Paid Clinical Trials Paid Clinical Trials > Browse Categories > Medications / Interventions > Cc > Cyclophosphamide

Cyclophosphamide

Cyclophosphamide

All Categories Medications / Interventions » Cc » Cyclophosphamide


  • Neoadjuvant Study of Sequential Eribulin Followed by FAC Compared to Sequential Paclitaxel Followed by FEC in Early Stage Breast Cancer Not Overexpressing HER-2

    Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Eribulin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Eisai Inc.
    Not yet recruiting - verified May 2012
  • Double Cord vs. Haploidentical (BMT CTN #1101)

    Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Burkitt's Lymphoma;   Follicular Lymphoma;   Hodgkin Lymphoma;   Mantle Cell Lymphoma
    Interventions:   Drug: Biological/Vaccine: Haploidentical BMT;   Drug: Double Cord Blood Transplantation
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Not yet recruiting - verified May 2012
  • Pancreatic Tumor Cell Vaccine (GVAX), Low Dose Cyclophosphamide, Fractionated Stereotactic Body Radiation Therapy (SBRT), and FOLFIRINOX Chemotherapy in Patients With Resected Adenocarcinoma of the Pancreas

    Condition:   Pancreatic Cancer
    Interventions:   Drug: Cyclophosphamide;   Biological: PANC 10.05 pcDNA-1/GM-Neo and PANC 6.03 pcDNA-1/GM-Neo vaccine;   Radiation: Stereotactic Body Radiation (SBRT);   Drug: FOLFIRINOX
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Not yet recruiting - verified May 2012
  • Vemurafenib and White Blood Cell Therapy for Advanced Melanoma

    Conditions:   Metastatic Cancer;   Melanoma
    Interventions:   Drug: Vemurafenib;   Drug: Young TIL;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Potentiation of Cetuximab by Tregs Depletion With CSA in Advanced Head & Neck Cancer

    Conditions:   Head and Neck Cancer;   Head and Neck Squamous Cell Carcinoma
    Interventions:   Drug: Cyclophosphamide;   Drug: Cetuximab
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified April 2012
  • Treating Cancer With Anti-mesothelin Modified Lymphocytes

    Conditions:   Metastatic Cancer;   Pancreatic Cancer;   Mesothelioma
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Biological: Aldesleukin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Crohn's Allogeneic Transplant Study

    Condition:   Crohn's Disease
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: mycophenolic acid enteric coated;   Drug: tacrolimus;   Other: quality-of-life assessment;   Other: laboratory biomarker analysis;   Drug: fludarabine phosphate;   Procedure: allogeneic bone marrow transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center
    Not yet recruiting - verified April 2012
  • A Study Combining Ibrutinib With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With CD20-Positive B-Cell Non Hodgkin Lymphoma

    Condition:   CD20-positive B-cell Non-Hodgkin Lymphoma
    Interventions:   Drug: Part 1, Cohort 1;   Drug: Part 1, Cohort 2;   Drug: Part 1, Cohort 3;   Drug: Part 2, Cohort 1;   Drug: Part 2, Cohort 2
    Sponsors:   Janssen Research & Development, LLC;   Janssen Research & Development, LLC;   Pharmacyclics
    Not yet recruiting - verified May 2012
  • A Safety/Feasibility Trial of the Addition of the Humanized Anti-GD2 Antibody (hu14.18K322A) With and Without Natural Killer Cells to Chemotherapy in Children and Adolescents With Recurrent/Refractory Neuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Biological: Humanized anti-GD2 antibody;   Drug: Chemotherapy;   Other: Cytokines;   Biological: Natural killer cells
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified April 2012
  • Eribulin in Combination With Cyclophosphamide in Patients With Solid Tumor Malignancies

    Conditions:   Malignant Solid Tumour;   Breast Cancer Nos Metastatic Recurrent;   Neuropathy
    Intervention:   Drug: Eribulin in Combination w/ Cyclophosphamide
    Sponsors:   University of California, San Francisco;   University of California, San Francisco;   Eisai Inc.
    Not yet recruiting - verified March 2012
  • Docetaxel and Cyclophosphamide Compared to Anthracycline-Based Chemotherapy in Treating Women With HER2-Negative Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: AC regimen;   Drug: TAC regimen;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

    Condition:   HIV
    Interventions:   Genetic: SB-728-T;   Genetic: SB-728-T;   Genetic: SB-728-T
    Sponsors:   Sangamo Biosciences;   Sangamo Biosciences
    Recruiting - verified April 2012
  • Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

    Condition:   Multiple Myeloma
    Interventions:   Drug: DPACE (Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Procedure: Transplant 1 (Velcade, Thalidomide, Dexamethasone, Melphalan);   Procedure: Transplant 2 (Velcade, Gemcitabine, Carmustine, Dexamethasone, Melphalan);   Drug: Consolidation VDT-PACE (Velcade, Dexamethasone, Thalidomide, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide);   Drug: Maintenance Year 1 (Velcade, Thalidomide, Dexamethasone OR Velcade, Revlimid, Dexamethasone OR Velcade, Cyclophosphamide, Dexamethasone in 28 day cycles x 12);   Drug: Maintenance Year 2 (Revlimid and Dexamethasone in 28 day cycles x 12)
    Sponsors:   University of Iowa;   University of Iowa;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Impact of Body Weight on Pharmacokinetic Analysis of Doxorubicin + Cyclophosphamide in Breast Cancer

    Condition:   Breast Cancer
    Intervention:  
    Sponsors:   University of Texas Southwestern Medical Center;   University of Texas Southwestern Medical Center;   Texas Tech University Health Sciences Center
    Not yet recruiting - verified January 2012
  • Effect of Weight on the Population Pharmacokinetic Analysis of Doxorubicin and Cyclophosphamide

    Conditions:   Breast Cancer;   Obesity
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Texas Tech University Health Sciences Center;   Texas Tech University Health Sciences Center;   University of Texas
    Recruiting - verified April 2012
  • Rituximab and Combination Chemotherapy in Treating Patients With Previously Untreated High- or High-Intermediate-Risk Diffuse Large B-Cell Lymphoma

    Conditions:   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: prednisone;   Other: laboratory biomarker analysis;   Other: pharmacological study
    Sponsors:   Fox Chase Cancer Center;   Fox Chase Cancer Center;   Genentech
    Not yet recruiting - verified March 2012
  • A Two-Step Approach to Bone Marrow Transplant Using Cells From Two Partially-Matched Relatives

    Conditions:   Hematologic Malignancy;   Leukemia;   Acute Lymphoblastic Leukemia;   ALL;   Acute Myelogenous Leukemia;   AML;   Chronic Lymphocytic Leukemia;   CLL;   Lymphoma;   Hodgkin's Lymphoma;   Non-hodgkin's Lymphoma;   Myeloma
    Interventions:   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate Mofetil (MMF);   Biological: Hematopoietic Stem Cell Transplant (HSCT)
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
    Recruiting - verified April 2012
  • Trial of Eribulin/Cyclophosphamide or Docetaxel/Cyclophosphamide as Neoadjuvant Therapy in Locally Advanced HER2-Negative Breast Cancer

    Condition:   Locally Advanced HER2-Negative Breast Cancer
    Interventions:   Drug: Eribulin Mesylate;   Drug: Cyclophosphamide;   Drug: Docetaxel
    Sponsors:   Sarah Cannon Research Institute;   Sarah Cannon Research Institute;   Eisai Inc.
    Not yet recruiting - verified March 2012
  • Metronomic Therapy in Patients With Metastatic Melanoma

    Condition:   Metastatic Melanoma
    Interventions:   Drug: vinblastine;   Drug: Cyclophosphamide;   Drug: dacarbazine
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Dartmouth-Hitchcock Medical Center
    Recruiting - verified February 2012
  • MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I

    Condition:   Breast Cancer
    Interventions:   Drug: TAC chemotherapy;   Drug: TC chemotherapy;   Drug: Dose Dense AC or FEC100 followed by paclitaxel or docetaxel chemotherapy;   Drug: TCH chemotherapy
    Sponsors:   Agendia;   Agendia;   University of South Florida;   University of Miami
    Recruiting - verified January 2012
  • Cyclophosphamide, Topotecan, and Bevacizumab (CTB) in Patients With Relapsed/Refractory Ewing's Sarcoma and Neuroblastoma

    Conditions:   Neuroblastoma;   Sarcoma
    Intervention:   Drug: Cyclophosphamide, Topotecan, and Bevacizumab
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech;   Children's Mercy Hospital Kansas City;   Penn State University;   University of Colorado Health Sciences Center and The Children's Hospital;   Johns Hopkins Medical Center Sidney Kimmel Comprehensive Cancer Center;   Phoenix Children's Hospital Center for Cancer & Blood Disorders;   Alberta Children's Hospital;   MD Anderson Cancer Center Orlando;   M.D. Anderson Cancer Center
    Recruiting - verified December 2011
  • Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Conditions:   Contiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Biological: ofatumumab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: vincristine sulfate;   Drug: cytarabine;   Procedure: autologous hematopoietic stem cell transplantation;   Drug: methotrexate
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute;   National Comprehensive Cancer Network
    Recruiting - verified April 2012
  • Melanoma Treatment With White Blood Cells That Destroy MART Expressing Tumor Cells

    Conditions:   Mestatic Melanoma;   Skin Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cycolphosphamide;   Drug: Aldesleukin;   Drug: MART-1 Reactive CD8+ PBL
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma

    Condition:   Mantle Cell Lymphoma
    Intervention:   Other: R-CHOP-14R-HIDAC,followed by RIT/HDT/ASCR.
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   GlaxoSmithKline
    Recruiting - verified March 2012
  • Safety Study of HPV DNA Vaccine to Treat Head and Neck Cancer Patients

    Condition:   HPV-related Head and Neck Cancer
    Intervention:   Biological: pNGVL-4a-CRT/E7 (detox) DNA vaccine
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Institute of Dental and Craniofacial Research (NIDCR);   Milton J. Dance, Jr. Head and Neck Center at Greater Baltimore Medical Center;   Ichor Medical System Incorporated
    Recruiting - verified April 2012
  • Umbilical Cord Transplantation for the Elderly Population

    Condition:   Hematologic Malignancies
    Intervention:   Biological: StemEx
    Sponsors:   Loyola University;   Loyola University;   Gamida Cell ltd
    Recruiting - verified November 2011
  • Autologous T Cells, Low-Dose Recombinant Interferon Gamma, Cyclophosphamide, and Low-Dose Aldesleukin in Treating Patients With Soft Tissue Sarcoma That is Metastatic or Cannot Be Removed By Surgery

    Conditions:   Adult Liposarcoma;   Adult Synovial Sarcoma;   Recurrent Adult Soft Tissue Sarcoma;   Stage III Adult Soft Tissue Sarcoma;   Stage IV Adult Soft Tissue Sarcoma
    Interventions:   Biological: recombinant interferon gamma;   Biological: aldesleukin;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Biological: NY-ESO-1-specific T lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • T-Cell Depleted Double UCB for Refractory AML

    Conditions:   Acute Myelogenous Leukemia;   Refractory Acute Myelogenous Leukemia
    Interventions:   Drug: Allopurinol;   Drug: Fludarabine;   Radiation: Total body irradiation;   Drug: Cyclophosphamide;   Drug: Levetiracetam;   Drug: Busulfan;   Biological: Umbilical Cord Blood Transplantation;   Biological: Interleukin-2
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • L-BLP25 (Stimuvax) in Prostate Cancer

    Condition:   Prostate Cancer
    Interventions:   Drug: Radiation;   Drug: Androgen Deprivation Therapy (ADT);   Other: Standard of care;   Drug: L-BLP25
    Sponsors:   EMD Serono;   EMD Serono
    Recruiting - verified December 2011
  • In-vivo Regulatory T Cell Enhancement With Cyclophosphamide and Sirolimus With or Without Vidaza (Azacitidine) for Steroid-refractory Acute Graft-versus-host Disease

    Condition:   Graft Versus Host Disease
    Interventions:   Drug: Cyclophospahmide and Sirolimus;   Drug: Low dose IL-2, Cyclophosphamide and Sirolimus;   Drug: Low dose IL-2, low dose Vidaza, cyclophosphamide & Sirolimus
    Sponsors:   Hackensack University Medical Center;   Hackensack University Medical Center
    Recruiting - verified October 2011
  • Neoadjuvant Trial of Eribulin Followed by Dose Dense Doxorubicin and Cyclophosphamide for Her2-negative, Locally Advanced Breast Cancer

    Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors;   Cancer of the Breast;   Neoplasms, Breast;   Tumors, Breast
    Interventions:   Drug: Eribulin;   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   Emory University;   Emory University;   Eisai Inc.
    Recruiting - verified December 2011
  • Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease

    Condition:   Sickle Cell Disease
    Intervention:   Drug: CD34 selected T-cell depleted allogeneic stem cell transplantation
    Sponsors:   New York Medical College;   New York Medical College;   Children's Hospital & Research Center Oakland;   Columbia University;   Medical College of Wisconsin;   Washington University School of Medicine;   Tufts University;   University of California, San Francisco;   Miltenyi Biotec GmbH;   Otsuka Pharmaceutical Development & Commercialization, Inc.;   FDA Office of Orphan Products Development
    Recruiting - verified April 2012
  • White Blood Cells With Anti-EGFR-III for Malignant Gliomas

    Conditions:   Malignant Glioma;   Glioblastoma;   Brain Cancer
    Interventions:   Genetic: Anti-EGFRvIII CAR (PG13-139-CD8-CD28BBZ (F10) transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • A Pilot Study of the Administration of Young Tumor Infiltrating Lymphocytes Following a Non-Myeloablative Lymphocyte Depleting Chemotrheraphy Regimen in Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young TIL
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • Autologous Stem Cell Systemic Sclerosis Immune Suppression Trial

    Condition:   Scleroderma
    Interventions:   Procedure: Rituximab sandwich regiment followed by SCT;   Procedure: cyclophosphamide regiment followed by SCT
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • International Pleuropulmonary Blastoma (PPB) Treatment and Biology Registry

    Condition:   Pleuropulmonary Blastoma
    Interventions:   Drug: Vincristine;   Drug: Dactinomycin;   Drug: Cyclophosphamide;   Drug: Ifosfamide;   Drug: Doxorubicin
    Sponsors:   Children's Hospitals and Clinics of Minnesota;   Children's Hospitals and Clinics of Minnesota
    Recruiting - verified November 2011
  • Pomalidomide in Combination With High Dose Dexamethasone and Oral Cyclophosphamide

    Condition:   Myeloma
    Interventions:   Drug: Pomalidomide;   Drug: Dexamethasone;   Drug: Cyclophosphamide
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute;   Celgene Corporation
    Recruiting - verified May 2012
  • A Study to Evaluate the Use of Chloroquine in Combination With VELCADE and Cyclophosphamide in Patients With Relapsed and Refractory Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Drug: Velcade;   Drug: Chloroquine
    Sponsors:   New York University School of Medicine;   New York University School of Medicine;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2012
  • Safety Study of a Melanoma Vaccine (GVAX) With or Without Cyclophosphamide in Patients With Surgically Resected Melanoma

    Condition:   Melanoma
    Interventions:   Biological: melanoma GVAX;   Drug: Cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   The John P. Hussman Foundation
    Recruiting - verified September 2011
  • Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Noncutaneous Extranodal Lymphoma;   Peripheral T-cell Lymphoma;   Philadelphia Chromosome Negative Chronic Myelogenous Leukemia;   Post-transplant Lymphoproliferative Disorder;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: busulfan;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Hyper-CVAD and Ponatinib in Ph-Positive and/or BCR-ABL Positive Acute Lymphoblastic Leukemia (ALL)

    Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ponatinib;   Drug: G-CSF (Filgrastim);   Drug: Rituximab;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Solu-medrol ( Methyl Prednisolone);   Drug: Citrovorum (Leucovorin);   Drug: Prednisone;   Drug: Pegfilgrastim (Neulasta)
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Ariad Pharmaceuticals
    Recruiting - verified May 2012
  • NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma

    Condition:   Lymphoblastic Lymphoma
    Interventions:   Drug: prednisone, vincristine, daunorubicin, PEG-asparaginase, methotrexate, hydrocortisone, cytarabine (IT-MH)A treatment, cyclophosphamide, cytarabine, thioguanine;   Drug: PEG- asparaginase, High-Dose Methotrexate (HD-MTX) and Mercaptopurine;   Drug: Dexamethasone, Doxorubicin; Vincristine; Mercaptopurine; PEG- Asparaginase, Cyclophosphamide, and Cytarabine;   Drug: dexamethasone, cytarabine, etoposide, pegaspargase, clofarabine, cyclophosphamide;   Drug: Intrathecal chemotherapy
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National University, Singapore
    Recruiting - verified April 2012
  • Consolidation Therapy With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19 in Patients With Chronic Lymphocytic Leukemia Following Upfront Chemotherapy With Pentostatin, Cyclophosphamide and Rituximab

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Biological: modified T cells
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2012
  • Cancer Vaccines CRS-207 and GVAX Pancreas for Metastatic Pancreatic Adenocarcinoma

    Condition:   Pancreatic Cancer
    Interventions:   Drug: GVAX Pancreas, Cyclophosphamide and CRS-207;   Drug: GVAX Pancreas and Cyclophosphamide
    Sponsors:   Aduro BioTech, Inc.;   Aduro BioTech, Inc.;   Johns Hopkins University
    Recruiting - verified May 2012
  • MLN4924 Compared With MLN4924 Plus Chemotherapy for Large B-cell Lymphoma

    Conditions:   Lymphoma, Diffuse Large-Cell B-cell;   Diffuse, Large B-cell Lymphoma;   Lymphoma, Diffuse Large-Cell;   Large-Cell Lymphoma, Diffuse
    Interventions:   Drug: MLN4924;   Drug: Etoposide;   Drug: Prednisone;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Rituximab;   Drug: Filgrastim
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Not yet recruiting - verified April 2012
  • A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

    Conditions:   ER Positive, Her2 Negative Breast Cancer Patients;   Triple Negative Breast Cancer Patients
    Interventions:   Drug: MM-121 (SAR256212) plus paclitaxel;   Drug: Paclitaxel
    Sponsors:   Merrimack Pharmaceuticals;   Merrimack Pharmaceuticals;   Sanofi-Aventis
    Recruiting - verified April 2012
  • Phase 1-2 Study of a Cancer Vaccine to Treat Patients With Advanced Stage Ovarian, Fallopian or Peritoneal Cancer

    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Peritoneal Cancer
    Interventions:   Biological: DPX-Survivac;   Drug: low dose cyclophosphamide (oral)
    Sponsors:   ImmunoVaccine Technologies, Inc.;   ImmunoVaccine Technologies, Inc.
    Recruiting - verified December 2011
  • A Study of RO5072759 (GA101) in Combination With CHOP Chemotherapy in Patients With Previously Untreated Advanced Diffuse Large B-Cell Lymphoma (GATHER)

    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: RO50722759;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone
    Sponsors:   Genentech;   Genentech
    Recruiting - verified May 2012
  • High-Dose Cyclophosphamide and Anti-Thymocyte Globulin Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Systemic Scleroderma

    Condition:   Systemic Scleroderma
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Biological: anti-thymocyte globulin;   Other: questionnaire administration;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Biological: filgrastim;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified March 2012
  • Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bendamustine hydrochloride;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Allogeneic Transplant in HIV Patients (BMT CTN 0903)

    Conditions:   Leukemia;   Lymphoma;   HIV
    Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI);   Drug: Fludarabine;   Drug: Busulfan, Fludarabine, Cyclophosphamide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified March 2012
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk Acute Lymphoblastic Leukemia

    Conditions:   Cognitive/Functional Effects;   Leukemia;   Neurotoxicity;   Pain;   Therapy-related Toxicity
    Interventions:   Drug: clofarabine;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: hydrocortisone sodium succinate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: selective external radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Peptide-based Glioma Vaccine IMA950 in Patients With Glioblastoma

    Condition:   Glioblastoma
    Interventions:   Drug: Cyclophosphamide;   Biological: IMA950 plus GM-CSF;   Biological: IMA950;   Drug: Imiquimod
    Sponsors:   immatics Biotechnologies GmbH;   immatics Biotechnologies GmbH;   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Cyclophosphamide and Pulse Dexamethasone With Rapamycin or Hydroxychloroquine

    Condition:   Myeloma
    Interventions:   Drug: Hydroxychloroquine;   Drug: Rapamycin
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified May 2012
  • A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

    Conditions:   Hematologic Malignancies;   Acute Leukemia;   Myelodysplastic Syndrome (MDS);   Specific Subtypes of Refractory Anemia (RA) or Refractory Anemia With Ringed Sideroblasts(RARS) Subtypes;   Myeloproliferative Disorder (MPD);   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Myeloma;   Aplastic Anemia
    Interventions:   Drug: Fludarabine;   Drug: Thiotepa;   Radiation: Total Body Irradiation (TBI);   Biological: Donor Lymphocyte Infusion (DLI);   Drug: Cyclophosphamide (CY);   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Device: Hematopoietic stem cell transplantation
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
    Recruiting - verified January 2012
  • Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

    Conditions:   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: Intravenous Recombinant Human IL-15 (rhIL-15)
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2012
  • Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

    Conditions:   Light Chain Deposition Disease (LCDD or MIDD);   Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD);   Monoclonal Immunoglobulin Deposition Disease (MIDD);   Amyloidosis
    Intervention:   Drug: Bortezomib/Dexamethasone (BD), Followed By Autologous STC & Maintenance Bortezomib/Dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2012
  • Inotuzumab Ozogamycin in Elderly Acute Lymphoblastic Leukemia (ALL)

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Inotuzumab Ozogamycin;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Pegfilgrastim;   Drug: Methotrexate;   Drug: Ara-C;   Drug: Inotuzumab Ozogamycin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Pfizer
    Recruiting - verified April 2012
  • Use of IL-15 After Chemotherapy and Lymphocyte Transfer in Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Tumor Infiltrating Lymphocytes;   Drug: IL-15
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: Aldesleukin;   Biological: Tumor Infiltrating Lymphocytes
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • NK Cell Based Non-Myeloablative Transplantation in Acute Myeloid Diseases

    Conditions:   Acute Myeloid Leukemia;   Myelodysplastic Syndrome
    Interventions:   Drug: Preparative Regimen;   Biological: NK Cell Product;   Drug: Interleukin-2;   Biological: Donor CD34+ Cells;   Biological: Anti-thymocyte globulin
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Palonosetron, Ondansetron, and Dexamethasone for Delayed Nausea and Vomiting in Autologous Transplant Patients

    Condition:   Chemotherapy-induced Nausea and Vomiting
    Intervention:   Drug: Palonosetron, ondansetron, dexamethasone
    Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified March 2012
  • Hyper CVAD Plus Ofatumumab in CD - 20 Positive Acute Lymphoblastic Leukemia (ALL)

    Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Ofatumumab;   Drug: Methotrexate;   Drug: Cytarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   GlaxoSmithKline
    Recruiting - verified May 2012
  • SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma

    Condition:   Mesothelioma
    Interventions:   Drug: Pentostatin;   Drug: Cyclophosphamide;   Drug: SS1P
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Infusion of Allogeneic Umbilical Cord Blood-Derived CD19-Specific T Cells

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Procedure: T-Cell Infusion;   Drug: Rituxan;   Drug: Melphalan;   Drug: Thiotepa;   Drug: Fludarabine;   Drug: ATG;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation (TBI)
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Not yet recruiting - verified May 2012
  • PET-Directed Therapy in Treating Patients With Limited-Stage Diffuse Large B-Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis;   Radiation: fludeoxyglucose F 18;   Radiation: selective external radiation therapy;   Radiation: yttrium Y 90 ibritumomab tiuxetan
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

    Condition:   Hematological Malignancies
    Interventions:   Radiation: Total Body Irradiation;   Drug: Cyclophosphamide;   Drug: Tacrolimus;   Drug: Mycophenolate mofetil;   Drug: Fludarabine;   Drug: Thiotepa;   Genetic: Hematopoietic stem cell transplantation
    Sponsors:   Thomas Jefferson University;   Thomas Jefferson University
    Recruiting - verified January 2012
  • Tumor Cell Vaccines and ISCOMATRIX(Trademark) With Chemotherapy After Tumor Removal

    Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancy
    Interventions:   Biological: Epigenetically Modified Autologous Tumor;   Drug: Cyclophosphamide;   Drug: Celecoxib
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    Conditions:   Hodgkin's Lymphoma;   Leukemia;   Myelodysplastic Syndrome(MDS);   Multiple Myeloma;   Non Hodgkin's Lymphoma
    Intervention:   Procedure: Bone Marrow Transplant
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2012
  • Reduced Intensity Conditioning Versus Myeloablative Conditioning for Acute Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901)

    Condition:   Leukemia, Myelocytic, Acute
    Interventions:   Drug: Fludarabine and Busulfan (Flu/Bu);   Drug: Fludarabine and Melphalan (Flu/Mel);   Drug: Busulfan and Fludarabine (Bu/Flu);   Drug: Busulfan and Cyclophosphamide (Bu/Cy);   Drug: Cyclophosphamide and Total Body Irradiation (Cy/TBI)
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI);   Blood and Marrow Transplant Clinical Trials Network
    Recruiting - verified March 2012
  • Vaccine Therapy Following Therapeutic Autologous Lymphocytes and Cyclophosphamide in Treating Patients With Metastatic Melanoma

    Conditions:   Recurrent Melanoma;   Stage IV Melanoma
    Interventions:   Drug: cyclophosphamide;   Biological: aldesleukin;   Biological: autologous tumor cell vaccine;   Other: laboratory biomarker analysis;   Other: immunologic technique;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Biological: therapeutic autologous lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Pilot Study of Lupron to Improve Immune Function After Allogeneic Bone Marrow Transplantation

    Conditions:   Acute Lymphocytic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome RAEB 1
    Interventions:   Drug: Lupron;   Drug: 18F FLT;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Tacrolimus;   Drug: Total Body Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: everolimus;   Drug: prednisone;   Drug: vincristine sulfate;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   North Central Cancer Treatment Group;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases

    Conditions:   Chronic Leukemia;   Acute Leukemia;   Hodgkin's Disease;   Non-Hodgkin's Lymphoma;   Myelodysplastic Syndrome
    Intervention:   Procedure: Peripheral Blood Stem Cell Transplant
    Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified September 2011
  • Unrelated Donor Stem Cell Transplantation

    Conditions:   Severe Aplastic Anemia;   Paroxysmal Nocturnal Hemoglobinuria;   Acute Myelogenous Leukemia;   Acute Lymphoblastic Leukemia;   Myelodysplastic Syndromes;   Myeloproliferative Syndromes;   Chronic Myelogenous Leukemia;   Hodgkin's Lymphoma;   Non-Hodgkin's Lymphoma;   Multiple Myeloma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Large Granulocytic Leukemia
    Intervention:   Procedure: Allogeneic transplantation
    Sponsors:   Scripps Health;   Scripps Health
    Recruiting - verified June 2011
  • Combination Chemotherapy and Pralatrexate as First-Line Therapy in Treating Patients With Non-Hodgkin Lymphoma

    Conditions:   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic T-cell Lymphoma;   Peripheral T-cell Lymphoma
    Interventions:   Drug: prednisone;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Drug: pralatrexate;   Other: laboratory biomarker analysis;   Genetic: comparative genomic hybridization;   Genetic: gene expression analysis;   Genetic: nucleic acid sequencing;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Genetic: microarray analysis;   Genetic: RNA analysis
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer

    Condition:   Her2normal
    Intervention:   Drug: eribulin mesylate
    Sponsors:   Eisai Inc.;   Eisai Inc.
    Recruiting - verified February 2012
  • Stage I/II Nasal NK Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Radiation: Radiation;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen

    Conditions:   Hematologic Malignancies;   Disorder Related to Transplantation;   Hematopoietic Malignancy
    Intervention:   Genetic: Preparative Regimen
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified December 2011
  • Hyper-CVAD With Liposomal Vincristine in Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: Rituximab;   Drug: Imatinib;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Mesna;   Drug: VSLI;   Drug: Solu-Medrol;   Drug: Methotrexate;   Drug: Ara-C;   Drug: G-CSF;   Drug: Pegfilgrastim;   Drug: Dexamethasone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Talon Therapeutics, Inc
    Not yet recruiting - verified May 2012
  • Prospective Randomized Study of Cell Therapy for Metastatic Melanoma Using Short-Term Cultured Tumor Infiltrating Lymphocytes Plus IL-2 Following Either a Non-Myeloablative Lymphocyte Depleting Chemotherapy Regimen Alone or in Conjunction w/1200 TBI

    Conditions:   Metastatic Melanoma;   Skin Cancer
    Interventions:   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Young Tumor Infiltrating Lymphocytes;   Procedure: 1200 Gy Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Autologous T-Cells Combined With Autologous OC-DC Vaccine in Ovarian Cancer

    Conditions:   Ovarian Carcinoma;   Fallopian Tube Cancer;   Primary Peritoneal Cancer
    Interventions:   Biological: OC-DC vaccine;   Drug: Bevacizumab;   Drug: cyclophosphamide 300 mg/m2/d for 3 days;   Drug: fludarabine 30 mg/m2/d for 3 days;   Drug: ex vivo CD3/CD28-costimulated vaccine-primed peripheral blood autologous T cells
    Sponsors:   Abramson Cancer Center of the University of Pennsylvania;   Abramson Cancer Center of the University of Pennsylvania
    Recruiting - verified June 2011
  • Tumor Cell Vaccine for Patients Undergoing Surgery for Sarcomas, Melanomas, Germ Cell Tumors, or Malignancies That Have Metastasized to the Lungs, Pleura, or Mediastinum

    Conditions:   Sarcoma;   Melanoma;   Epithelial Malignancies;   Pleural Malignancies
    Intervention:   Biological: Allogenic Tumor Cell Vaccine (K562)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • ABT-888 With Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal or Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, Triple-Negative Breast Cancer, and Low-Grade Non-Hodgkin's Lymphoma

    Conditions:   Ovarian;   Primary Peritoneal;   Serous Carcinoma;   Triple-Negative Breast;   Fallopian Tube
    Interventions:   Drug: ABT-888 with Cyclophospharmide;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • A Study of GA101 (RO5072759) in Combination With Chemotherapy in Patients With Previously Untreated Chronic Lymphocytic Leukemia (GALTON)

    Condition:   Chronic Lymphocytic Leukemia
    Interventions:   Drug: bendamustine;   Drug: cyclophosphamide;   Drug: Fludarabine;   Drug: RO5072759
    Sponsors:   Genentech;   Genentech
    Recruiting - verified March 2012
  • A Phase I Study of NK Cell Infusion Following Allogeneic Peripheral Blood Stem Cell Transplantation From Related or Matched Unrelated Donors in Pediatric Patients With Solid Tumors and Leukemias

    Conditions:   Leukemia;   Lymphoma;   Neuroblastoma;   Sarcoma;   Desmoplastic Small Round Cell Tumor
    Interventions:   Drug: Melphalan;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Prednisone;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Filgrastim;   Biological: NK-DLI Infusions
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • A Study of Obinutuzumab (RO5072759) in Combination With CHOP Chemotherapy Versus MabThera/Rituxan (Rituximab) With CHOP in Patients With CD20-Positive Diffuse Large B-Cell Lymphoma

    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: RO5072759;   Drug: rituximab [MabThera/Rituxan];   Drug: CHOP chemotherapy
    Sponsors:   Hoffmann-La Roche;   Hoffmann-La Roche
    Recruiting - verified May 2012
  • Patient-donor Vaccination in the Context of Allogeneic Bone Marrow Transplant With Post-transplant Cyclophosphamide

    Condition:   Transplant-Related Cancer
    Interventions:   Biological: Hepatitis A;   Biological: PCV 13
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Biological: trastuzumab;   Drug: cyclophosphamide;   Drug: docetaxel;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   National Cancer Institute (NCI);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • IMA901 in Patients Receiving Sunitinib for Advanced/Metastatic Renal Cell Carcinoma

    Condition:   Metastatic Renal Cell Carcinoma
    Interventions:   Drug: Sunitinib;   Biological: IMA901 plus GM-CSF;   Drug: Cyclophosphamide
    Sponsors:   immatics Biotechnologies GmbH;   immatics Biotechnologies GmbH
    Recruiting - verified May 2012
  • Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral Cavity

    Conditions:   Squamous Cell Carcinoma (SCC) of the Oral Cavity;   Squamous Cell Carcinoma of the Soft Palate
    Interventions:   Biological: LI plus CIZ;   Other: Standard of Care (SOC);   Biological: LI + SOC
    Sponsors:   CEL-SCI Corporation;   CEL-SCI Corporation;   Teva Pharmaceutical Industries;   Orient Europharma Co., Ltd.
    Recruiting - verified January 2012
  • Targeting Complement Activation in Antineutrophil Cytoplasmic Autoantibodies (ANCA)-Vasculitis - Eculizumab

    Condition:   Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
    Interventions:   Drug: Standard of care treatment;   Drug: eculizumab
    Sponsors:   University of North Carolina, Chapel Hill;   University of North Carolina, Chapel Hill;   Alexion Pharmaceuticals;   National Institutes of Health (NIH);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified December 2011
  • Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: alemtuzumab;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide phosphate;   Drug: fludarabine phosphate;   Drug: leucovorin calcium;   Drug: melphalan;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: vincristine sulfate;   Genetic: polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Sapacitabine, Cyclophosphamide, Rituximab for Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma (CLL/SLL) With Deletion (11q22-23)

    Condition:   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Rituximab;   Drug: Sapacitabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Cyclacel Pharmaceuticals, Inc.
    Recruiting - verified January 2012
  • GnRH-a for Ovarian Protection During CYC Therapy for Rheumatic Diseases

    Conditions:   Lupus Erythematosus, Systemic;   Systemic Vasculitis;   Isolated Angiitis of Central Nervous System;   Lung Disease With Systemic Sclerosis;   Lung Disease Interstitial Diffuse
    Interventions:   Drug: depot leuprolide acetate 3.75 mg;   Drug: Placebo
    Sponsors:   University of Michigan;   Joseph Mccune;   National Institutes of Health (NIH)
    Recruiting - verified February 2012
  • Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies

    Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified August 2011
  • Post-transplant Cyclophosphamide and Sirolimus Following RIC Transplant

    Condition:   Hematologic Neoplasms
    Intervention:   Procedure: Allogeneic Hematopoietic Stem Cell Transplantation
    Sponsors:   Northside Hospital, Inc.;   Northside Hospital, Inc.;   Blood and Marrow Transplant Group of Georgia
    Recruiting - verified March 2012
  • Umbilical Cord Blood Transplant for Children With Lymphoid Hematological Malignancies

    Conditions:   Lymphoid Hematological Malignancies;   Umbilical Cord Blood Transplant
    Intervention:   Drug: Cytoxan/TBI/Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified August 2011
  • Viral Therapy in Treating Young Patients With Relapsed or Refractory Solid Tumors

    Condition:   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: wild-type reovirus;   Drug: cyclophosphamide;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • Cell Therapy for Metastatic Melanoma Using CD8 Enriched Tumor Infiltrating Lymphocytes

    Conditions:   Skin Cancer;   Metastatic Melanoma
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Other: Gene Transfer
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Combination Chemotherapy in Treating Patients With Non-Metastatic Extracranial Ewing Sarcoma

    Conditions:   Brain and Central Nervous System Tumors;   Kidney Cancer;   Sarcoma
    Interventions:   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Vinorelbine Ditartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory Rhabdomyosarcoma

    Condition:   Sarcoma
    Interventions:   Biological: bevacizumab;   Drug: cyclophosphamide;   Drug: temsirolimus;   Drug: vinorelbine tartrate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Treating Metastatic Cancer With Anti-VEGFR2 Gene Engineered CD8+ Lymphocytes

    Conditions:   Metastatic Cancer;   Metastatic Melanoma;   Renal Cancer
    Interventions:   Genetic: Anti-VEGFR2 CAR CD8 plus PBL;   Drug: Cyclophosphamide;   Drug: Aldesleukin;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Ex Vivo-Expanded HER2-Specific T Cells and Cyclophosphamide After Vaccine Therapy in Treating Patients With HER2-Positive Stage IV Breast Cancer

    Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Biological: HER-2/neu peptide vaccine;   Drug: cyclophosphamide;   Biological: ex vivo-expanded HER2-specific T cells;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Other: immunoenzyme technique
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2012
  • Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

    Condition:   Hematologic Malignancies
    Interventions:   Other: Fludarabine, Cytoxan, TBI, Sirolimus;   Other: Fludarabine, Cytoxan, TBI, Sirolimus + MMF;   Other: Fludarabine, Cytoxan, TBI, Tacrolimus + MMF
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2012
  • Vorinostat and Combination Chemotherapy With Rituximab in Treating Patients With Previously Untreated HIV-Related Diffuse Large B-Cell Non-Hodgkin Lymphoma

    Conditions:   Lymphoma;   Nonneoplastic Condition
    Interventions:   Biological: rituximab;   Drug: EPOCH regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat;   Other: R-CHOP regimen
    Sponsors:   National Cancer Institute (NCI);   AIDS Associated Malignancies Clinical Trials Consortium;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Cyclophosphamide Plus Cyclosporine in Treatment-na ve Severe Aplastic Anemia

    Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Severe Aplastic Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclosporine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2011
  • Risk-Adapted Chemotherapy in Younger Patients With Newly Diagnosed Standard-Risk Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • A Pilot Study of Fludarabine Plus Cyclophosphamide in Refractory Severe Aplastic Anemia

    Conditions:   Aplastic Anemia;   Neutropenia;   Pancytopenia;   Severe Aplastic Anemia;   Refractory Severe Aplastic Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified July 2011
  • Allogeneic Tumor Cell Vaccination With Oral Metronomic Cytoxan in Patients With High-Risk Neuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Biological: Neuroblastoma Vaccine;   Drug: Cytoxan
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified April 2012
  • Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

    Conditions:   Relapsed Lymphoma;   B Cell Non-Hodgkin Lymphoma;   Refractory Lymphoma;   High Risk Chronic Lymphocytic Leukemia
    Interventions:   Drug: Rituximab;   Biological: Interleukin-2;   Biological: Natural killer cells;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Fludarabine
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Tandem Auto-Allo Transplant for Lymphoma

    Conditions:   Diffuse, Large B-Cell, Lymphoma;   Lymphoma, Low-Grade;   T-Cell Lymphoma;   Mantle-Cell Lymphoma;   Hodgkin's Lymphoma;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
    Interventions:   Drug: Busulfan;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Mesna;   Drug: Phenytoin;   Drug: Ursodiol;   Other: Infusion of autologous peripheral blood stem cells;   Drug: Neupogen;   Drug: Fludarabine;   Drug: Busulfan;   Other: Peripheral blood stem cell transplant;   Drug: Tacrolimus;   Drug: Sirolimus;   Drug: Methotrexate
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Dana-Farber Cancer Institute
    Recruiting - verified April 2012
  • Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Myelodysplastic Syndromes;   Chronic Eosinophilic Leukemia;   Chronic Neutrophilic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Procedure: umbilical cord blood transplantation;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Procedure: ex vivo-expanded cord blood progenitor cell infusion;   Radiation: total-body irradiation;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Pilot Study of Reduced-Intensity Hematopoietic Stem Cell Transplant of DOCK8 Deficiency

    Condition:   DOCK8 Deficiency
    Interventions:   Drug: Fludarabine;   Procedure: Allogeneic HSC transplant;   Drug: Cyclophosphamide;   Procedure: Total Body Irradiation (TBI)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin

    Condition:   Neuroblastoma
    Interventions:   Drug: busulfan;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: irinotecan hydrochloride;   Drug: isotretinoin;   Drug: melphalan;   Drug: topotecan hydrochloride;   Drug: vincristine sulfate;   Other: pharmacological study;   Other: questionnaire administration;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Procedure: therapeutic conventional surgery;   Radiation: 3-dimensional conformal radiation therapy;   Radiation: external beam radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: iobenguane I 131
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • A Phase II Study Using Short-Term Cultured, CD8+-Enriched Autologous Tumor-infiltrating Lymphocytes Following a Lymphocyte Depleting Regimen in Metastatic Digestive Tract Cancers

    Conditions:   Metastatic Colorectal Cancer;   Metastatic Gastric Cancer;   Metastatic Pancreatic Cancer;   Metastatic Hepatocellular Carcinoma;   Metastatic Cholangiocarcinoma
    Interventions:   Drug: CD8+ young TIL;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Laboratory-Treated T Cells After Chemotherapy in Treating Women With Stage II or Stage III Breast Cancer Undergoing Surgery

    Condition:   Breast Cancer
    Interventions:   Biological: HER2Bi-armed activated T cells;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel;   Other: laboratory biomarker analysis;   Procedure: neoadjuvant therapy;   Procedure: therapeutic conventional surgery
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • A Phase II Study of Ofatumumab-Based Induction Chemoimmunotheraphy Followed by Consolidation Ofatumumab Immunotherapy in Previously Untreated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Conditions:   Small Lymphocytic Lymphoma;   CLL (Chronic Lymphocytic Leukemia)
    Interventions:   Drug: Fludarabine Phosphate;   Biological: Ofatumumab;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI);   University of Virginia;   GlasoSmithKline
    Recruiting - verified April 2012
  • Pilot Study of Allogeneic Tumor Cell Vaccine With Metronomic Oral Cyclophosphamide and Celecoxib in Patients Undergoing Resection of Lung and Esophageal Cancers, Thymic Neoplasms, and Malignant Pleural Mesotheliomas

    Conditions:   Lung Cancer;   Esophageal Cancer;   Malignant Pleural Mesothelioma;   Thymoma;   Thymic Carcinoma
    Interventions:   Biological: Allogeneic Tumor Cell Vaccine (K562);   Drug: Celecoxib;   Drug: cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Adoptive Transfer of Autologous T Cells Targeted to Prostate Specific Membrane Antigen (PSMA) for the Treatment of Castrate Metastatic Prostate Cancer (CMPC)

    Condition:   Prostate Cancer
    Interventions:   Biological: engineered autologous T cells;   Drug: cyclophosphamide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Department of Defense
    Recruiting - verified March 2012
  • Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

    Conditions:   Hematologic Malignancy;   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia in Blast Crisis;   Anemia, Refractory, With Excess of Blasts;   Chronic Myeloproliferative Disease;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Marginal Zone B-cell Lymphoma;   Follicular Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle-Cell Lymphoma;   Prolymphocytic Lymphoma;   Large Cell Non-Hodgkin's Lymphoma;   Lymphoblastic Lymphoma;   Burkitt's Lymphoma;   High Grade Non-Hodgkin's Lymphoma
    Interventions:   Biological: Treg cells;   Biological: CD3+ Teff cells;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Radiation: Total body irradiation;   Biological: Umbilical cord blood transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Not yet recruiting - verified December 2011
  • Immunochemotherapy, Zevalin, and Bone Marrow Transplant for Follicular Lymphoma

    Condition:   Follicular Lymphoma
    Intervention:   Other: Combination of treatment modalities
    Sponsors:   St. Louis University;   St. Louis University
    Recruiting - verified May 2010
  • Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: bleomycin sulfate;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Other: laboratory biomarker analysis;   Procedure: computed tomography;   Radiation: fludeoxyglucose F 18;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies

    Conditions:   Acute Lymphoblastic Leukemia;   Acute Myelogenous Leukemia;   Myelodysplastic Syndrome;   Multiple Myeloma
    Interventions:   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system;   Device: CliniMACS Fractionation system
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified December 2011
  • High Dose Chemotherapy and Stem Cell Transplant for Non-Hodgkin's Lymphoma or Central Nervous System (CNS) Lymphoma

    Conditions:   Non-Hodgkin's Lymphoma;   CNS Lymphoma
    Intervention:   Procedure: High-dose chemotherapy with autologous stem cell transplant
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital;   Genentech;   Otsuka America Pharmaceutical;   Dana-Farber Cancer Institute
    Recruiting - verified April 2012
  • Allogeneic Natural Killer (NK) Cells for Ovarian, Fallopian Tube, Peritoneal and Metastatic Breast Cancer

    Conditions:   Ovarian Cancer;   Fallopian Tube Cancer;   Primary Peritoneal Cancer;   Breast Cancer
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclosporine;   Biological: Natural killer cells;   Drug: IL-2;   Drug: Methylprednisolone;   Drug: Methylprednisolone;   Drug: Interleukin-2
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Maintenance Chemotherapy or Observation Following Induction Chemotherapy and Radiation Therapy in Treating Younger Patients With Newly Diagnosed Ependymoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: vincristine sulfate;   Other: clinical observation;   Radiation: 3-dimensional conformal radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Lenalidomide and Cyclophosphamide in Treating Patients With Previously Treated Hormone-Refractory Prostate Cancer

    Conditions:   Adenocarcinoma of the Prostate;   Hormone-resistant Prostate Cancer;   Recurrent Prostate Cancer
    Interventions:   Drug: lenalidomide;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Procedure: quality-of-life assessment;   Other: questionnaire administration
    Sponsors:   University of Nebraska;   University of Nebraska;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Minimally Differentiated Myeloid Leukemia (M0);   Adult Acute Monoblastic Leukemia (M5a);   Adult Acute Monocytic Leukemia (M5b);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Erythroleukemia (M6a);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Adult Pure Erythroid Leukemia (M6b);   B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Childhood Acute Lymphoblastic Leukemia;   Blastic Phase Chronic Myelogenous Leukemia;   Burkitt Lymphoma;   Childhood Acute Erythroleukemia (M6);   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Megakaryocytic Leukemia (M7);   Childhood Acute Minimally Differentiated Myeloid Leukemia (M0);   Childhood Acute Monoblastic Leukemia (M5a);   Childhood Acute Monocytic Leukemia (M5b);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Secondary Myelofibrosis;   Splenic Marginal Zone Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage IV Chronic Lymphocytic Leukemia;   T-cell Adult Acute Lymphoblastic Leukemia;   T-cell Childhood Acute Lymphoblastic Leukemia;   T-cell Large Granular Lymphocyte Leukemia;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: double-unit umbilical cord blood transplantation;   Other: cytogenetic analysis;   Procedure: bone marrow aspiration;   Other: fluorescence in situ hybridization;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: anti-thymocyte globulin;   Drug: methylprednisolone;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center
    Recruiting - verified January 2012
  • Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

    Conditions:   Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive
    Interventions:   Drug: rituximab;   Drug: etoposide;   Drug: cyclophosphamide;   Drug: doxorubicin;   Drug: vincristine;   Drug: prednisone;   Drug: filgrastim
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified September 2011
  • A Phase 1/2 Study of PXD101 (Belinostat) in Combination With Cisplatin, Doxorubicin and Cyclophosphamide in the First Line Treatment of Advanced or Recurrent Thymic, Malignancies

    Conditions:   Thymoma;   Thymic Carcinoma
    Interventions:   Drug: Belinostat;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Study of Neoadjuvant Chemotherapy With Nanoparticle Albumin Bound Paclitaxel, Doxorubicin and Cyclophosphamide (NAC) in Patients With Stages II-III Breast Cancer

    Condition:   Stages II-III Breast Cancer
    Interventions:   Drug: Nanoparticle Albumin Bound Paclitaxel;   Drug: doxorubicin;   Drug: cyclophosphamide
    Sponsors:   University of South Alabama;   University of South Alabama;   Celgene Corporation
    Recruiting - verified August 2011
  • Plerixafor and Filgrastim Following Cyclophosphamide for Stem Cell Mobilization in Patients With Multiple Myeloma

    Conditions:   Refractory Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: plerixafor;   Biological: filgrastim;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center
    Recruiting - verified January 2012
  • Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

    Conditions:   Multiple Myeloma;   Stage I Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: carfilzomib;   Drug: cyclophosphamide;   Drug: thalidomide;   Drug: dexamethasone
    Sponsors:   Mayo Clinic;   Mayo Clinic
    Recruiting - verified April 2012
  • Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic Rhabdomyosarcoma

    Condition:   Sarcoma
    Interventions:   Biological: cixutumumab;   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: ifosfamide;   Drug: irinotecan hydrochloride;   Drug: temozolomide;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma

    Condition:   Lymphoma, B-Cell
    Interventions:   Drug: inotuzumab ozogamicin+rituximab +cyclophosphamide+vincristine+prednisone;   Drug: inotuzumab ozogamicin+rituximab+gemcitabine+cisplatinum+dexamethasone
    Sponsors:   Pfizer;   Pfizer;   UCB, Inc.
    Recruiting - verified May 2012
  • Low-Dose Conditioning Followed by Donor Stem Cell Transplant in Treating Patients With Severe Systemic Sclerosis

    Condition:   Systemic Scleroderma
    Interventions:   Drug: fludarabine phosphate;   Radiation: total-body irradiation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Biological: rituximab;   Drug: cyclophosphamide;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Not yet recruiting - verified May 2012
  • Precursor B Cell Acute Lymphoblastic Leukemia (B-ALL) Treated With Autologous T Cells Genetically Targeted to the B Cell Specific Antigen CD19

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Biological: gene-modified T cells targeted to B-ALL tumor cells
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified March 2012
  • Allogeneic Bone Marrow Transplant for Inherited Metabolic Disorders

    Conditions:   Mucopolysaccharidosis;   Hurler Syndrome;   Hunter Syndrome;   Maroteaux-Lamy Syndrome;   Sly Syndrome;   Alpha Mannosidosis;   Fucosidosis;   Aspartylglucosaminuria;   Adrenoleukodystrophy (ALD);   Globoid Cell Leukodystrophy (GLD);   Krabbe Disease;   Metachromatic Leukodystrophy (MLD);   Sphingolipidoses;   Peroxisomal Disorders
    Interventions:   Drug: Campath-1H;   Drug: Cyclophosphamide;   Drug: Busulfan;   Procedure: Allogeneic stem cell transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Mature B-Cell Lymphoma And Leukemia Study III

    Condition:   Mature B-Cell Lymphoma
    Interventions:   Drug: COPAD;   Drug: COP, COPD M3, CYM;   Drug: COP, COPADM8, CYVE
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified April 2012
  • I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer

    Conditions:   Breast Neoplasms;   Breast Cancer;   Breast Tumors
    Interventions:   Drug: Neratinib;   Drug: ABT-888;   Drug: Standard Therapy;   Drug: AMG 386;   Drug: AMG 479 (Ganitumab) plus Metformin
    Sponsors:   Foundation for the National Institutes of Health;   Foundation for the National Institutes of Health
    Recruiting - verified December 2011
  • Panitumumab, Nab-paclitaxel and Carboplatin for HER2 Negative Inflammatory Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Panitumumab;   Drug: Nab-paclitaxel;   Drug: Carboplatin;   Drug: 5-Fluorouracil;   Drug: Epirubicin;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Celgene Corporation;   Amgen
    Recruiting - verified April 2012
  • Stem Cell Transplant for Epidermolysis Bullosa

    Condition:   Epidermolysis Bullosa
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Anti-thymocyte globulin;   Drug: Cyclosporine A;   Drug: Mycophenolate mofetil;   Procedure: Hematopoietic stem cell transplant;   Procedure: Mesenchymal stem cell transplant;   Radiation: Total body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified May 2012
  • Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Conditions:   Acute Undifferentiated Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Megakaryoblastic Leukemia (M7);   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Erythroleukemia (M6a);   Adult Pure Erythroid Leukemia (M6b);   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Refractory Multiple Myeloma;   Stage II Multiple Myeloma;   Stage III Multiple Myeloma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Procedure: peripheral blood stem cell transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: laboratory biomarker analysis;   Procedure: flow cytometry;   Radiation: total-body irradiation;   Genetic: fluorescence in situ hybridization;   Genetic: western blotting;   Procedure: polymerase chain reaction;   Biological: filgrastim
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: anti-thymocyte globulin;   Biological: rituximab;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methotrexate;   Drug: sirolimus;   Drug: tacrolimus;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Chemotherapy Plus Cetuximab Followed by Surgical Resection in Patients With Locally Advanced or Recurrent Thymoma

    Conditions:   Thymoma;   Clinical Masaoka Stage II-IVA
    Intervention:   Drug: Cetuximab, Cisplatin, Doxorubicin & Cyclophosphamide
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified January 2012
  • Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Conditions:   Hematopoietic/Lymphoid Cancer;   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage 0 Chronic Lymphocytic Leukemia;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: pentostatin;   Drug: cyclophosphamide;   Biological: ofatumumab;   Procedure: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: protein expression analysis
    Sponsors:   Mayo Clinic;   Mayo Clinic
    Recruiting - verified April 2012
  • Laboratory-Treated T Cells After Second-Line Chemotherapy in Treating Women With HER2/Neu-Negative Metastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Biological: HER2Bi-armed activated T cells;   Drug: Cyclophosphamide;   Other: Laboratory biomarker analysis
    Sponsors:   Barbara Ann Karmanos Cancer Institute;   Barbara Ann Karmanos Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified November 2011
  • Risk-Adapted Allogeneic Stem Cell Transplantation For Mixed Donor Chimerism In Patients With Non-Malignant Diseases

    Conditions:   Bone Marrow Failure;   Osteopetrosis;   Fanconi Anemia;   Severe Combined Immunodeficiency
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide 40;   Drug: Cyclophosphamide 30
    Sponsors:   Columbia University;   Columbia University
    Recruiting - verified October 2011
  • Intercontinental Multidisciplinary Registry and Treatment Optimization Study for Choroid Plexus Tumors

    Conditions:   Brain Cancer;   Choroid Plexus Tumors
    Interventions:   Drug: Carboplatin;   Drug: Cisplatin;   Drug: Cyclophosphamide;   Drug: Dactinomycin;   Drug: Doxorubicin;   Drug: Etoposide;   Drug: Irinotecan;   Drug: Leucovorin;   Drug: Methotrexate;   Drug: Temozolomide;   Drug: Vincristine
    Sponsors:   Tufts Medical Center;   Tufts Medical Center
    Recruiting - verified April 2012
  • Mismatched Transplantation Using High-dose Post-transplant Cyclophosphamide

    Conditions:   Blood Stem Cell Transplant Failure;   Leukemia;   Hematologic Malignancies
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Melphalan;   Drug: Mesna;   Drug: Rituximab;   Procedure: Stem Cell Transplantation;   Drug: Thiotepa;   Drug: Tacrolimus;   Drug: Mycofenolate mofetil
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Autologous Peripheral Blood Stem Cell Transplant Followed by Donor Bone Marrow Transplant in Treating Patients With High-Risk Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   B-cell Chronic Lymphocytic Leukemia;   Burkitt Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Peripheral T-cell Lymphoma;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Drug: melphalan;   Procedure: autologous-allogeneic tandem hematopoietic stem cell transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: allogeneic bone marrow transplantation;   Genetic: fluorescence in situ hybridization;   Other: flow cytometry;   Genetic: RNA analysis;   Other: laboratory biomarker analysis;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Procedure: allogeneic peripheral blood mononuclear stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Phase II Randomized Trial Evaluating Neoadjuvant Therapy With Neratinib or Trastuzumab Followed by Postoperative Trastuzumab in Women With Locally Advanced HER2-positive Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: Paclitaxel;   Drug: Trastuzumab;   Drug: Neratinib;   Drug: Trastuzumab (post surgery);   Drug: Doxorubicin;   Drug: Cyclophosphamide
    Sponsors:   National Surgical Adjuvant Breast and Bowel Project (NSABP);   National Surgical Adjuvant Breast and Bowel Project (NSABP);   Wyeth Pharmaceuticals, Inc., a Pfizer Company
    Recruiting - verified February 2012
  • Pegaspargase and Combination Chemotherapy in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: imatinib mesylate;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: vincristine sulfate;   Other: pharmacological study
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified March 2011
  • Valproic Acid in Combination With FEC100 for Primary Therapy in Patients With Breast Cancer

    Condition:   Breast Cancer
    Intervention:   Drug: VPA FEC100
    Sponsors:   University of California, San Francisco;   University of California, San Francisco;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified March 2012
  • Lymphodepletion Plus Adoptive Cell Transfer With High Dose IL-2 in Patients With Metastatic Melanoma

    Condition:   Metastatic Melanoma
    Interventions:   Procedure: Surgery;   Drug: Administration of Lymphodepletion;   Other: Adoptive Cell Transfer;   Drug: High Dose IL-2
    Sponsors:   H. Lee Moffitt Cancer Center and Research Institute;   H. Lee Moffitt Cancer Center and Research Institute
    Recruiting - verified January 2012
  • EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

    Condition:   Leukemia-Lymphoma, Adult T-Cell
    Intervention:   Drug: Etoposide, Vincristine, Doxorubicin, Prednisone, Cyclophosphamide (EPOCH) with Bortezomib and Raltegravir
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified May 2012
  • A Phase I Trial Using Cyclophosphamide, Rituximab and Revlimid (CR2) for the Treatment of Relapsed/Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Small Lymphocytic Lymphoma (SLL)

    Conditions:   Leukemia, Lymphocytic, Chronic, B-Cell;   Chronic Lymphocytic Leukemia;   Lymphoma, Small Lymphocytic
    Intervention:   Drug: Lenalidomide, Rituximab, and Cyclophosphamide
    Sponsors:   Emory University;   Emory University;   Celgene Corporation
    Recruiting - verified November 2011
  • Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and Fludarabine

    Conditions:   Aplastic Anemia;   Leukemia;   Myelodysplastic Syndrome
    Intervention:   Other: Busulfan, fludarabine, & cyclophosphamide with immunosuppression with ATG and cyclosporine. CD34+ T-cell depleted peripheral blood stem cell transplant
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Children's Hospital Boston;   Children's Hospital Medical Center, Cincinnati;   Children's Hospital and Health System Foundation, Wisconsin;   Rockefeller University;   Fred Hutchinson Cancer Research Center
    Recruiting - verified November 2011
  • Nonmyeloablative Haploidentical Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Severe Congenital Anemias Including Sickle Cell Disease and Beta-Thalassemia

    Conditions:   Peripheral Blood Stem Cell Transplantation;   Anemia, Sickle Cell;   Graft-Versus-Host Disease;   Sirolimus (Rapamune(Registered Trademark));   Alemtuzumab (Campath(Registered Trademark))
    Interventions:   Procedure: PBMC Transplant;   Drug: Alemtuzumab (Campath(Registered Trademark));   Drug: Sirolimus (Rapamune(Registered Trademark));   Drug: Cyclophosphamide (Cytoxan(Registered Trademark));   Procedure: Low Dose Irradiation
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified June 2011
  • Trial of Nelarabine, Etoposide and Cyclophosphamide in Relapsed T-cell ALL and T-cell LL

    Conditions:   Relapsed T-Cell Acute Lymphoblastic Leukemia;   Relapsed T-Cell Lymphoblastic Lymphoma
    Interventions:   Drug: Nelarabine;   Drug: Etoposide;   Drug: Cyclophosphamide;   Drug: Methotrexate;   Drug: Filgrastim
    Sponsors:   Therapeutic Advances in Childhood Leukemia Consortium;   Therapeutic Advances in Childhood Leukemia Consortium;   GlaxoSmithKline
    Recruiting - verified November 2011
  • Cyclophosphamide and Vaccine Therapy With or Without Trastuzumab in Treating Patients With Metastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Biological: allogeneic GM-CSF-secreting breast cancer vaccine;   Biological: trastuzumab;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Vorinostat, Rituximab, and Combination Chemotherapy In Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: prednisone;   Drug: vincristine sulfate;   Drug: vorinostat;   Other: R-CHOP regimen;   Other: laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified July 2011
  • RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia

    Conditions:   Leukemia;   Acute Lymphocytic Leukemia
    Interventions:   Drug: Everolimus (RAD001);   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Mesna;   Drug: Methotrexate;   Drug: Ara-C (Cytarabine);   Drug: Solu-Medrol;   Drug: G-CSF
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Novartis
    Recruiting - verified November 2011
  • Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

    Conditions:   Mantle Cell Lymphoma;   Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • Sickle Cell Disease Conditioning for Bone Marrow Transplant

    Conditions:   Bone Marrow Transplantation;   Sickle Cell Disease
    Intervention:   Drug: fludarabine
    Sponsors:   Emory University;   Emory University
    Recruiting - verified November 2011
  • Umbilical Cord Blood Transplant for Congenital Pediatric Disorders

    Condition:   Congenital Pediatric Disorders
    Interventions:   Drug: Busulfan;   Drug: Cytoxan;   Drug: Fludarabine
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
    Recruiting - verified August 2011
  • Optimized Donor Selection, Nonmyeloablative BMT for B-cell Lymphomas With Post-transplantation Cy and Rituximab

    Conditions:   Lymphoma;   B-cell Lymphoma;   Non Hodgkin Lymphoma;   Chronic Lymphocytic Leukemia
    Intervention:   Drug: Bone marrow transplantation
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center
    Recruiting - verified January 2012
  • Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Procedure: autologous hematopoietic stem cell transplantation
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Evaluate Trastuzumab Plus Standard Chemotherapy Given Before Surgery in Breast Cancer Patients With Low HER 2 Expression

    Condition:   Breast Cancer
    Interventions:   Drug: nab-paclitaxel;   Drug: trastuzumab;   Drug: Doxorubicin;   Drug: cyclophosphamide
    Sponsors:   University of Kansas;   University of Kansas;   Celgene Corporation
    Recruiting - verified October 2011
  • Exemestane or Docetaxel-cytoxan in Low Recurrence Score Cancers

    Condition:   Breast Cancer
    Interventions:   Drug: Exemestane;   Drug: Docetaxel, cytoxan
    Sponsors:   Emory University;   Emory University;   Pfizer
    Recruiting - verified February 2012
  • Induction Therapy With Cytarabine, High-Dose Mitoxantrone and Dasatinib for Patients With Philadelphia-Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Intervention:   Drug: Dasatinib, Mitoxantrone, Cytarabine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified January 2012
  • Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

    Condition:   Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
    Interventions:   Drug: Vc-RCHOP;   Drug: RCHOP
    Sponsors:   Millennium Pharmaceuticals, Inc.;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified January 2012
  • Phase II Trial of LMB-2, Fludarabine and Cyclophosphamide for Adult T-Cell Leukemia

    Condition:   Adult T-Cell Leukemia (ATL)
    Interventions:   Drug: LMB-2;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: LMB-2, anti-Tac(Fv)-PE38
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Low-Intensity Stem Cell Transplantation With Multiple Lymphocyte Infusions to Treat Advanced Kidney Cancer

    Conditions:   Renal Cell Carcinoma;   Graft-Versus-Host Disease;   Engraftment Syndrome
    Interventions:   Drug: Pentostatin;   Drug: Sirolimus;   Drug: Cyclophosphamide;   Procedure: Allogeneic Hematopoietic Stem Cell Transplant;   Procedure: Th2 Cell Transplantation;   Drug: Th2 Cells in Allogeneic HSCT
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Phase I/II Study of B Cell Malignancies Using T Cells Expressing an Anti-CD19 Chimeric Receptor: Assessment of the Impact of Lymphocyte Depletion Prior to T Cell Transfer

    Conditions:   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma;   Follicular Lymphoma;   Large Cell Lymphoma
    Interventions:   Genetic: Anti-CD19-CAR Transduced PBL;   Drug: Aldesleukin;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: PG13-CD19-H3 (anti-CD19-CAR) transduced PBL)
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

    Conditions:   Renal Cancer;   Kidney Cancer
    Interventions:   Genetic: 2G-1 TCR Retroviral Vector-Transduced lyn;   Drug: Aldesleukin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: (PG13-A(F/K-F-SGSG-T2a-B (opt) (2G-1 TCR) retroviral vector-transduced lymphocyte
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified October 2011
  • Vorinostat, Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic

    Conditions:   B-cell Chronic Lymphocytic Leukemia;   Contiguous Stage II Small Lymphocytic Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Stage I Chronic Lymphocytic Leukemia;   Stage I Small Lymphocytic Lymphoma;   Stage II Chronic Lymphocytic Leukemia;   Stage III Chronic Lymphocytic Leukemia;   Stage III Small Lymphocytic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Small Lymphocytic Lymphoma
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Biological: rituximab;   Drug: vorinostat
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Effectiveness of a Blood Stem Cell Transplant That Uses Low Dose Chemotherapy in People With Relapsed Follicular Non-Hodgkin's Lymphoma (BMT CTN #0701)

    Condition:   Lymphoma, Non-Hodgkin
    Intervention:   Biological: Hematopoietic Stem Cell Transplant
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Hematopoietic Stem Cell Transplant for Fanconi Anemia

    Condition:   Fanconi Anemia
    Intervention:   Device: CliniMACs device
    Sponsors:   Medical College of Wisconsin;   Medical College of Wisconsin;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified February 2012
  • Biomarkers in Predicting Outcome in Postmenopausal Women With Hormone Receptor-Positive, Node-Positive Breast Cancer Treated With Tamoxifen With or Without Cyclophosphamide, Doxorubicin, and Fluorouracil

    Condition:   Breast Cancer
    Interventions:   Genetic: comparative genomic hybridization;   Genetic: microarray analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: diagnostic laboratory biomarker analysis
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2008
  • N2007-02:Bevacizumab,Cyclophosphamide,& Zoledronic Acid in Patients W/ Recurrent or Refractory High-Risk Neuroblastoma

    Condition:   Neuroblastoma
    Interventions:   Drug: Bevacizumab;   Drug: cyclophosphamide;   Drug: zoledronic acid
    Sponsors:   New Approaches to Neuroblastoma Therapy Consortium;   New Approaches to Neuroblastoma Therapy Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

    Conditions:   Neuroblastoma;   Bone Marrow, Sympathetic Nervous System
    Intervention:   Other: cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified November 2011
  • Autologous T Lymphocytes Engrafted With a Chimeric Antigen Receptor Targeting the Kappa Light Chain

    Conditions:   Lymphoma;   Myeloma;   Leukemia
    Intervention:   Biological: Genetically modified T cells
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified April 2012
  • Laboratory-Treated T Cells and Ipilimumab in Treating Patients With Metastatic Melanoma

    Conditions:   Recurrent Melanoma;   Stage IV Melanoma
    Interventions:   Biological: ipilimumab;   Drug: cyclophosphamide;   Procedure: biopsy;   Biological: aldesleukin;   Other: immunohistochemistry staining method;   Genetic: polymerase chain reaction;   Other: immunoenzyme technique;   Biological: therapeutic allogeneic cytotoxic T lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Vorinostat, Isotretinoin, and Combination Chemotherapy in Treating Young Patients Who Have Undergone Surgery for Embryonal Tumors of the Central Nervous System

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: isotretinoin;   Drug: thiotepa;   Drug: vincristine sulfate;   Drug: vorinostat;   Radiation: Conformal radiation
    Sponsors:   Pediatric Brain Tumor Consortium;   Pediatric Brain Tumor Consortium;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Augmented Berlin-Frankfurt-Munster (BFM) Therapy for Adolescent/Young Adults With Acute Lymphoblastic Leukemia or Acute Lymphoblastic Lymphoma

    Conditions:   Lymphoblastic Leukemia;   Lymphoblastic Lymphoma
    Interventions:   Drug: Daunorubicin;   Drug: Vincristine;   Drug: PEG-asparaginase;   Drug: Intrathecal Methotrexate;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Mercaptopurine;   Drug: Methotrexate;   Drug: Doxorubicin;   Drug: Thioguanine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery

    Condition:   Breast Cancer
    Interventions:   Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Mismatched Donor Lymphocyte Infusions for Relapsed Disease Following Allogeneic Stem Cell Transplantation

    Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphoblastic, Acute;   Leukemia, Myelocytic, Chronic
    Interventions:   Other: Allogeneic Lymphocytes;   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Methylprednisolone;   Drug: Cyclosporine
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified November 2011
  • Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Doxorubicin, Cyclophosphamide, and Pegfilgrastim With or Without Bevacizumab in Treating Women With Inflammatory or Locally Advanced Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Combined Bone Marrow Transplantation (BMT) and Renal Transplant for Multiple Myeloma (MM) With End Stage Renal Disease (ESRD)

    Conditions:   Multiple Myeloma;   End Stage Renal Disease
    Interventions:   Drug: Cyclophosphamide, anti-thymocyte globulin, cyclosporine;   Procedure: Kidney transplant;   Radiation: Thymic irradiation;   Procedure: Bone marrow transplant from a related donor
    Sponsors:   Massachusetts General Hospital;   Massachusetts General Hospital
    Recruiting - verified April 2012
  • Nonmyeloablative Allo Stem Cell Transplant for Severe Autoimmune Diseases

    Conditions:   Systemic Lupus Erythematosus;   Systemic Sclerosis
    Intervention:   Procedure: Nonmyeloablative allogeneic stem cell transplant
    Sponsors:   Duke University;   Duke University
    Recruiting - verified February 2012
  • Trastuzumab, Cyclophosphamide, and Vaccine Therapy in Treating Patients With High-Risk or Metastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Biological: allogeneic GM-CSF-secreting breast cancer vaccine;   Biological: trastuzumab;   Drug: cyclophosphamide;   Other: flow cytometry;   Other: immunoenzyme technique;   Other: immunohistochemistry staining method;   Other: laboratory biomarker analysis;   Other: pharmacological study;   Procedure: biopsy
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Reduced Duration Stanford V Chemotherapy With or Without Low-Dose Tailored-Field Radiation Therapy For Favorable Risk Pediatric Hodgkin Lymphoma

    Condition:   Hodgkin Lymphoma
    Interventions:   Drug: Stanford V Chemotherapy;   Radiation: Radiation Therapy
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified March 2012
  • Trial Using Docetaxel Cytoxan in Breast Cancers With High Recurrence Scores

    Conditions:   Breast Neoplasms;   Breast Cancer;   Cancer of the Breast
    Intervention:   Drug: Docetaxel and Cytoxan
    Sponsors:   Emory University;   Emory University;   Sanofi-Aventis
    Recruiting - verified February 2012
  • Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: bleomycin sulfate;   Biological: filgrastim;   Drug: ABVD regimen;   Drug: BEACOPP regimen;   Drug: cyclophosphamide;   Drug: dacarbazine;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: prednisone;   Drug: procarbazine hydrochloride;   Drug: vinblastine sulfate;   Drug: vincristine sulfate;   Radiation: fludeoxyglucose F 18
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • CpG 7909/Montanide ISA 720 With or Without Cyclophosphamide in Combination Either With NY-ESO-1-derived Peptides or the NY-ESO-1 Protein for NY-ESO-1-expressing Tumors

    Condition:   NY-ESO-1-expressing Tumors
    Interventions:   Biological: Vaccine only;   Biological: Vaccine + cyclophosphamide;   Biological: Vaccine only;   Biological: Vaccine + cyclophosphamide;   Biological: Vaccine only;   Biological: Vaccine + cyclophosphamide
    Sponsors:   University of Pittsburgh;   University of Pittsburgh;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Pentostatin, Cyclophosphamide, and Rituximab With or Without Bevacizumab in Treating Patients With B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Biological: bevacizumab;   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: pentostatin
    Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • R-ICE and High-Dose Cyclophosphamide With PET/CT for Diffuse Large B-Cell Non-Hodgkin's Lymphoma

    Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: R-CHOP, R-CHOEP, R-EPOCH;   Drug: R-ICE, Cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Genentech
    Recruiting - verified January 2012
  • Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance L

    Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem cell transplant x 1 or x 2;   Drug: lenalidomide and dexamethasone
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Tufts Medical Center;   Lahey Clinic
    Recruiting - verified January 2012
  • Chemotherapeutic Agents in Brain/Breast

    Conditions:   Breast Cancer;   Metastatic Cancer
    Interventions:   Drug: capecitabine;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: gemcitabine hydrochloride;   Drug: lapatinib ditosylate;   Drug: paclitaxel;   Drug: vinorelbine ditartrate;   Drug: Trastuzumab
    Sponsors:   Case Comprehensive Cancer Center;   Case Comprehensive Cancer Center;   Department of Defense;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Safety Study of Bone Marrow Transplant Using Mismatched Tissue Followed by Chemotherapy

    Conditions:   MDS;   Leukemias;   Lymphomas
    Intervention:   Drug: Drug: busulfan, Cyclophosphamide, Total Body Irradiation
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   Otsuka Pharmaceutical Co., Ltd.;   National Center for Research Resources (NCRR)
    Recruiting - verified January 2012
  • Combination Chemotherapy With or Without Donor Stem Cell Transplant in Treating Patients With Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: filgrastim;   Biological: graft versus host disease prophylaxis/therapy;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dasatinib;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: cytogenetic analysis;   Genetic: polymerase chain reaction;   Other: flow cytometry;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   National Cancer Institute (NCI);   Southwest Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Vaccine Therapy in Treating Patients With Stage IV Breast Cancer

    Conditions:   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
    Interventions:   Biological: HER-2/neu peptide vaccine;   Procedure: leukapheresis;   Biological: ex vivo-expanded HER2-specific T cells;   Drug: cyclophosphamide;   Other: laboratory biomarker analysis;   Biological: sargramostim;   Other: flow cytometry;   Other: immunoenzyme technique;   Genetic: gene expression analysis;   Genetic: polymerase chain reaction
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation, and Donor Bone Marrow Transplant Followed by Donor Natural Killer Cell Therapy, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Hematologic Cancer

    Conditions:   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Myelomonocytic Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Hepatosplenic T-cell Lymphoma;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome With Isolated Del(5q);   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Peripheral T-cell Lymphoma;   Plasma Cell Neoplasm;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Myelodysplastic Syndromes;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Childhood Small Noncleaved Cell Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Childhood Small Noncleaved Cell Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Childhood Small Noncleaved Cell Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Testicular Lymphoma;   Untreated Adult Acute Lymphoblastic Leukemia;   Untreated Adult Acute Myeloid Leukemia;   Untreated Childhood Acute Lymphoblastic Leukemia;   Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Biological: natural killer cell therapy;   Genetic: fluorescence in situ hybridization;   Genetic: cytogenetic analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Drug: Zolinza (vorinostat);   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisone
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Merck
    Recruiting - verified April 2012
  • Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: lenalidomide
    Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Hematopoietic Stem Cell Transplant in Devic's Disease

    Condition:   Devic's Disease
    Intervention:   Procedure: Hematopoietic stem cell transplantation
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.

    Condition:   Breast Cancer
    Intervention:   Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
    Sponsors:   University of Tennessee Cancer Institute;   University of Tennessee Cancer Institute;   National Comprehensive Cancer Network;   Celgene Corporation;   Genentech
    Recruiting - verified February 2012
  • Abatacept and Cyclophosphamide Combination Therapy for Lupus Nephritis

    Conditions:   Lupus Nephritis;   Lupus Erythematosus, Systemic
    Interventions:   Drug: Abatacept;   Drug: cyclophosphamide;   Drug: azathioprine;   Drug: prednisone;   Drug: abatacept placebo;   Drug: azathioprine placebo
    Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Institute of Allergy and Infectious Diseases (NIAID);   Immune Tolerance Network (ITN)
    Recruiting - verified November 2011
  • Allogeneic Transplantation For Severe Osteopetrosis

    Condition:   Severe Osteopetrosis
    Interventions:   Procedure: Stem Cell Transplantation;   Drug: Conditioning for transplantation-donor graft;   Radiation: Total Lymphoid Irradiation;   Drug: Conditioning for cord blood transplant
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Identifying Prognostic Factors in Frontline FCR for Patients With Chronic Lymphocytic Leukemia (CLL)

    Conditions:   Chronic Lymphocytic Leukemia;   Leukemia
    Interventions:   Drug: Fludarabine;   Drug: Cyclophosphamide;   Drug: Rituximab
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.

    Conditions:   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkins Lymphoma;   Chronic Myelogenous Leukemia
    Intervention:   Other: fludarabine, cyclophosphamide, thiotepa, radiation therapy, unrelated donor umbilical cord blood graft
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2012
  • Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

    Condition:   Hematologic Malignancies
    Intervention:   Procedure: Chemotherapy followed by Stem Cell Transplantation
    Sponsors:   Dartmouth-Hitchcock Medical Center;   Dartmouth-Hitchcock Medical Center
    Recruiting - verified January 2012
  • UARK 2008-01, Total Therapy 4 - A Phase III Trial for Low Risk Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: M-VTD-PACE;   Drug: TT3-LITE Regimen (L-TT3)
    Sponsors:   University of Arkansas;   University of Arkansas;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified April 2012
  • Vaccine Therapy With or Without Cyclophosphamide in Treating Patients Undergoing Chemotherapy and Radiation Therapy for Stage I or Stage II Pancreatic Cancer That Can Be Removed by Surgery

    Condition:   Pancreatic Cancer
    Interventions:   Biological: GVAX pancreatic cancer vaccine;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Unrelated Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Acute Myelomonocytic Leukemia (M4);   Childhood Anaplastic Large Cell Lymphoma;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Chronic Myelomonocytic Leukemia;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 1 Follicular Lymphoma;   Contiguous Stage II Grade 2 Follicular Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 1 Follicular Lymphoma;   Noncontiguous Stage II Grade 2 Follicular Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Noncontiguous Stage II Marginal Zone Lymphoma;   Noncontiguous Stage II Small Lymphocytic Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Anemia With Ringed Sideroblasts;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cytopenia With Multilineage Dysplasia;   Refractory Hairy Cell Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Diffuse Small Cleaved Cell Lymphoma;   Stage I Adult Hodgkin Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Hodgkin Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Childhood Small Noncleaved Cell Lymphoma;   Stage I Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage I Grade 1 Follicular Lymphoma;   Stage I Grade 2 Follicular Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Marginal Zone Lymphoma;   Stage I Multiple Myeloma;   Stage I Mycosis Fungoides/Sezary Syndrome;   Stage I Small Lymphocytic Lymphoma;   Stage II Adult Hodgkin Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Hodgkin Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage II Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage II Multiple Myeloma;   Stage II Mycosis Fungoides/Sezary Syndrome;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Diffuse Small Cleaved Cell Lymphoma;   Stage III Adult Hodgkin Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Hodgkin Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Chronic Lymphocytic Leukemia;   Stage III Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage III Grade 1 Follicular Lymphoma;   Stage III Grade 2 Follicular Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Marginal Zone Lymphoma;   Stage III Multiple Myeloma;   Stage III Mycosis Fungoides/Sezary Syndrome;   Stage III Small Lymphocytic Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Diffuse Small Cleaved Cell Lymphoma;   Stage IV Adult Hodgkin Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Hodgkin Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Chronic Lymphocytic Leukemia;   Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma;   Stage IV Grade 1 Follicular Lymphoma;   Stage IV Grade 2 Follicular Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Stage IV Marginal Zone Lymphoma;   Stage IV Mycosis Fungoides/Sezary Syndrome;   Stage IV Small Lymphocytic Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine Phosphate, and Total-Body Irradiation in Treating Patients With Hematologic Disease

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Blastic Phase Chronic Myelogenous Leukemia;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Primary Myelofibrosis;   Prolymphocytic Leukemia;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Anaplastic Large Cell Lymphoma;   Stage I Childhood Large Cell Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Anaplastic Large Cell Lymphoma;   Stage II Childhood Large Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Anaplastic Large Cell Lymphoma;   Stage III Childhood Large Cell Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Anaplastic Large Cell Lymphoma;   Stage IV Childhood Large Cell Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Drug: mycophenolate mofetil;   Radiation: total-body irradiation;   Procedure: umbilical cord blood transplantation;   Drug: cyclosporine;   Procedure: double-unit umbilical cord blood transplantation;   Other: laboratory biomarker analysis;   Procedure: biopsy;   Other: immunologic technique
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: rituximab;   Drug: bortezomib;   Drug: cyclophosphamide;   Drug: dexamethasone;   Other: questionnaire administration;   Procedure: quality-of-life assessment
    Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified March 2012
  • Therapy for Patients With Untreated Age-Adjusted International Prognostic Index Low-Intermediate Risk, High-Intermediate Risk, or High Risk Diffuse Large B Cell Lymphoma

    Condition:   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Etoposide, carboplatin, ifosfamide;   Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin;   Drug: Rituximab, Ifosfamide, Etoposide, Carboplatin, Stem Cell Collection, Mitoxantrone, Cyclophosphamide and etoposide, Carmustine
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center;   Genentech;   Columbia University
    Recruiting - verified January 2012
  • Immune Tolerance Induction Study

    Conditions:   Pompe Disease;   Glycogen Storage Disease Type II (GSD-II);   Glycogenesis 2 Acid Maltase Deficiency
    Interventions:   Biological: Myozyme (alglucosidase alfa);   Biological: Myozyme (alglucosidase alfa)
    Sponsors:   Genzyme;   Genzyme
    Recruiting - verified May 2012
  • Dendritic Cells (White Blood Cells) Vaccination for Advanced Melanoma

    Condition:   Melanoma
    Interventions:   Drug: cyclophosphamide;   Biological: Mature dendritic cell vaccine;   Biological: Mature dendritic cell vaccine
    Sponsors:   Washington University School of Medicine;   Washington University School of Medicine
    Recruiting - verified October 2011
  • A Phase II Study of Umbilical Cord Blood Transplantation

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma;   Aplastic Anemia
    Interventions:   Biological: Umbilical Cord Blood Transplantation After Myeloablative Conditioning;   Biological: Umbilical Cord Blood Transplantation After Reduced-Intensity Conditioning
    Sponsors:   Tufts Medical Center;   Tufts Medical Center
    Recruiting - verified May 2012
  • CD34+Selection for Partially Matched Family or Matched Unrelated Adult Donor Transplant

    Conditions:   Leukemia;   Lymphoma;   Bone Marrow Failure;   Immunodeficiencies;   Histiocytosis
    Interventions:   Drug: Full Intensity with TBI;   Drug: Full Intensity;   Drug: Reduced Intensity;   Drug: Reduced Intensity (Fanconi)
    Sponsors:   New York Medical College;   New York Medical College
    Recruiting - verified April 2012
  • Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia

    Conditions:   Leukemia;   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide (CTX);   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: Methotrexate (MTX);   Drug: Cytarabine;   Drug: G-CSF;   Drug: Mesna;   Drug: Pegylated asparaginase;   Drug: Pegfilgrastim;   Drug: Solumedrol
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified April 2012
  • Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

    Condition:   Lymphoma
    Interventions:   Biological: pegfilgrastim;   Biological: rituximab;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: lenalidomide;   Drug: prednisone;   Drug: vincristine sulfate;   Genetic: polymorphism analysis;   Other: laboratory biomarker analysis
    Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

    Conditions:   Burkitt's Lymphoma;   Burkitt'S-like Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Dexamethasone;   Drug: G-CSF;   Drug: Cytarabine;   Drug: Methotrexate
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified December 2011
  • Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia

    Conditions:   Refractory Solid Tumors;   Leukemia
    Interventions:   Drug: Bevacizumab;   Drug: Sorafenib;   Drug: Cyclophosphamide
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified January 2012
  • Pilot Study of Haploidentical Natural Killer Cell Infusions for Poor Prognosis Non-AML Hematologic Malignancies

    Conditions:   Acute Lymphoblastic Leukemia;   Chronic Myelogenous Leukemia;   Juvenile Myelomonocytic Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Other: NK Cell Infusion;   Biological: Immunotherapy;   Device: Miltenyi Biotec CliniMACS device;   Drug: Interleukin-2 (IL-2);   Drug: Clofarabine;   Drug: Cyclophosphamide;   Drug: Etoposide
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified December 2011
  • Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: etoposide phosphate;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate;   Genetic: mutation analysis;   Other: immunohistochemistry staining method;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: 3-dimensional conformal radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Pilot Study of Expanded, Donor Natural Killer Cell Infusions for Refractory Non-B Lineage Hematologic Malignancies and Solid Tumors

    Conditions:   Leukemia, Myeloid, Acute;   Leukemia, Lymphocytic, Acute, T-Cell;   Juvenile Myelomonocytic Leukemia Lymphoblastic;   T-cell Lymphoblastic Lymphoma;   Myelodysplastic Syndrome
    Interventions:   Procedure: Haploidentical donor derived natural killer cell infusion;   Drug: Chemotherapy (Cyclophosphamide, Fludarabine, Interleukin-2, Mesna);   Device: CliniMACS
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI);   Assisi Foundation
    Recruiting - verified March 2012
  • Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia

    Condition:   Leukemia
    Interventions:   Biological: sargramostim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: dexamethasone;   Drug: etoposide;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation;   Procedure: Bone marrow aspiration and biopsy;   Procedure: Apheresis
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2012
  • Cyclophosphamide, Fludarabine, and Antithymocyte Globulin Followed By Donor Stem Cell Transplant in Treating Patients With Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Procedure: hematopoietic stem cell transplantation;   Drug: methylprednisolone;   Drug: filgrastim;   Drug: cyclosporine;   Drug: Mycophenolate Mofetil
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011
  • Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning for Patients With Severe Systemic Sclerosis

    Conditions:   Systemic Scleroderma;   Severe Systemic Sclerosis
    Interventions:   Drug: fludarabine phosphate;   Drug: Mycophenolic Acid;   Drug: tacrolimus;   Radiation: total-body irradiation;   Procedure: bone marrow transplantation;   Procedure: reduced intensity allogeneic hematopoietic stem cell transplantation;   Procedure: quality-of-life assessment;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Procedure: biopsy;   Drug: cyclophosphamide
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Institute of Allergy and Infectious Diseases (NIAID)
    Recruiting - verified April 2012
  • A Phase I/II Trial of VR-CHOP in Lymphoma Patients

    Conditions:   Lymphoma, B-Cell;   Follicular Lymphoma
    Intervention:   Drug: rituximab, cyclophosphamide, doxorubicin, vincristine, bortezomib, prednisone
    Sponsors:   Emory University;   Emory University;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified March 2012
  • Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia

    Conditions:   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Biological: Stem cell infusion;   Radiation: Total body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2012
  • Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

    Conditions:   Neuroblastoma;   Medulloblastoma
    Interventions:   Drug: Nifurtimox;   Drug: Cyclophosphamide;   Drug: Topotecan
    Sponsors:   Van Andel Research Institute;   Giselle Sholler;   Bayer
    Recruiting - verified April 2012
  • Iodine I 131 Monoclonal Antibody BC8, Fludarabine Phosphate, Cyclophosphamide, Total-Body Irradiation and Donor Bone Marrow Transplant in Treating Patients With Advanced Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia or High-Risk Myelodysplastic Syndrome

    Conditions:   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Chronic Myelomonocytic Leukemia;   de Novo Myelodysplastic Syndromes;   Previously Treated Myelodysplastic Syndromes;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Acute Myeloid Leukemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Ringed Sideroblasts;   Refractory Cytopenia With Multilineage Dysplasia;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Radiation: iodine I 131 monoclonal antibody BC8;   Procedure: allogeneic bone marrow transplantation;   Drug: tacrolimus;   Drug: mycophenolate mofetil;   Other: laboratory biomarker analysis;   Other: flow cytometry;   Genetic: cytogenetic analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological Malignancy

    Conditions:   Cancer;   Leukemia;   Myelodysplastic Syndrome;   Non-Hodgkin's Lymphoma
    Interventions:   Drug: Fludarabine, Cyclophosphamide;   Procedure: Transplantation
    Sponsors:   Memorial Sloan-Kettering Cancer Center;   Memorial Sloan-Kettering Cancer Center
    Recruiting - verified January 2012
  • T-Reg Cell Kinetics for Patients Receiving Stem Cell Transplant

    Conditions:   Leukemia;   Hodgkin Lymphoma;   Non Hodgkin Lymphoma;   Myeloproliferative Disorders
    Interventions:   Drug: Ara C;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: TBI;   Biological: Campath-1h;   Procedure: Stem Cell Infusion;   Drug: Tacrolimus;   Drug: Methotrexate
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine
    Recruiting - verified April 2012
  • Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease

    Condition:   Chronic Granulomatous Disease
    Interventions:   Drug: Busulfan;   Biological: alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: cyclosporine;   Procedure: stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified May 2012
  • Allogeneic Stem Cell Transplant for Patients With Severe Aplastic Anemia

    Condition:   Aplastic Anemia
    Interventions:   Drug: Cytoxan;   Drug: Campath;   Radiation: Total Body Irradiation (TBI);   Drug: FK-506;   Drug: Methotrexate;   Procedure: Stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   The Methodist Hospital System;   Texas Children's Hospital;   Center for Cell and Gene Therapy, Baylor College of Medicine
    Recruiting - verified May 2012
  • Post Transplant For Patients Undergoing Matched Sibling Stem Cell Transplantation

    Conditions:   Leukemia;   Cancer;   Lymphoma
    Interventions:   Drug: Ara-C;   Drug: Cytoxan;   Drug: Mesna;   Radiation: TBI Fraction;   Procedure: Stem Cell Infusion;   Drug: Methotrexate;   Drug: Tacrolimus
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified April 2012
  • Allogeneic Bone Marrow Transplantation From HLA Identical Related Donors for Patients With Hemoglobinopathies

    Conditions:   Sickle Cell Disease;   Hemoglobin SC
    Interventions:   Procedure: ALLOGENEIC BMT/SCT Infusion;   Drug: Busulfan;   Biological: Campath 1H;   Drug: Cyclophosphamide and Mesna
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified May 2012
  • Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: allogeneic bone marrow transplantation;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: image-guided radiation therapy;   Radiation: intensity-modulated radiation therapy;   Radiation: tomotherapy
    Sponsors:   City of Hope Medical Center;   City of Hope Medical Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Stem Cell Transplant in Patients With Thalassemia

    Condition:   Thalassemia
    Interventions:   Drug: Busulfan;   Drug: Fludarabine;   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: MESNA;   Procedure: Bone marrow or stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital
    Recruiting - verified May 2012
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Cancer and Leukemia Group B;   National Cancer Institute (NCI);   Eastern Cooperative Oncology Group;   Southwest Oncology Group
    Recruiting - verified May 2012
  • Combination Chemotherapy With or Without Lestaurtinib in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: daunorubicin hydrochloride;   Drug: dexamethasone;   Drug: etoposide;   Drug: lestaurtinib;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: methylprednisolone;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

    Condition:   Retinoblastoma
    Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: thiotepa;   Drug: vincristine sulfate;   Procedure: autologous bone marrow transplantation;   Procedure: autologous hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Total Therapy Study XVI for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Prednisone, Vincristine, Daunorubicin, PEG-L-asparaginase, Erwinia L-asparaginase, Doxorubicin, Cyclophosphamide, Cytarabine, Thioguanine;   Drug: Clofarabine, Methotrexate, Mercaptopurine, Dexamethasone, Etoposide, Dasatinib
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Drug: lenalidomide (Revlimid®);   Drug: Cyclophosphamide;   Drug: Prednisone
    Sponsors:   Indiana University;   Indiana University School of Medicine;   Celgene Corporation
    Recruiting - verified November 2011
  • Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

    Conditions:   Myelodysplastic Syndrome;   Hodgkin's Lymphoma;   Non-Hodgkin's Disease;   Acute Leukemia;   Multiple Myeloma
    Interventions:   Drug: Cyclophosphamide;   Biological: rituximab;   Drug: Methotrexate;   Drug: Sirolimus;   Drug: Cyclosporine;   Drug: Doxorubicin hydrochloride;   Drug: Etoposide;   Drug: Fludarabine phosphate;   Drug: Prednisone;   Drug: Vincristine sulfate;   Drug: Cytarabine;   Drug: Tacrolimus;   Biological: Alemtuzumab
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified June 2011
  • Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer

    Conditions:   Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
    Interventions:   Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Rasburicase in Preventing Graft-Versus-Host Disease in Patients With Hematologic Cancer or Other Disease Undergoing Donor Stem Cell Transplant

    Conditions:   Chronic Myeloproliferative Disorders;   Graft Versus Host Disease;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Neoplasms
    Interventions:   Drug: busulfan;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: etoposide;   Drug: methotrexate;   Drug: rasburicase;   Drug: sirolimus;   Drug: tacrolimus;   Other: diagnostic laboratory biomarker analysis;   Other: flow cytometry;   Other: immunologic technique;   Procedure: allogeneic hematopoietic stem cell transplantation;   Procedure: peripheral blood stem cell transplantation;   Radiation: total-body irradiation
    Sponsors:   National Cancer Institute (NCI);   Massachusetts General Hospital
    Recruiting - verified April 2008
  • Primary Breast Cancer Occurring Concomitant With Pregnancy

    Conditions:   Breast Cancer;   Pregnancy
    Interventions:   Drug: 5-Fluorouracil;   Drug: Cyclophosphamide;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • Hyper-CVAD Plus Nelarabine in Untreated T-ALL/Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoblastic Lymphoma;   Leukemia, Lymphoblastic, Acute
    Interventions:   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Nelarabine
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified February 2012
  • Cord Blood Expansion on Mesenchymal Stem Cells

    Conditions:   Myelodysplastic Syndrome;   Leukemia
    Interventions:   Procedure: Cord Blood Infusion;   Drug: Busulfan;   Drug: Fludarabine;   Drug: Rituximab;   Other: ATG;   Drug: Cyclophosphamide;   Drug: Clofarabine;   Radiation: Total Body Irradiation (TBI);   Drug: Melphalan
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center
    Recruiting - verified May 2012
  • High-Dose Cyclophosphamide in Treating Patients With Acute Graft-Versus-Host Disease That Did Not Respond to Steroid Therapy

    Condition:   Graft Versus Host Disease
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant in Treating Patients With Sickle Cell Anemia and Other Blood Disorders

    Condition:   Sickle Cell Disease
    Interventions:   Biological: G-CSF;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: Sirolimus;   Procedure: Allogeneic bone marrow transplantation;   Radiation: total-body irradiation;   Drug: Levetiracetam
    Sponsors:   Sidney Kimmel Comprehensive Cancer Center;   Sidney Kimmel Comprehensive Cancer Center;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Autologous Followed by Non-myeloablative Allogeneic Transplantation for Non-Hodgkin's Lymphoma

    Condition:   Lymphoma, Non-Hodgkin
    Interventions:   Drug: Cyclophosphamide;   Drug: Carmustine;   Drug: Etoposide;   Drug: Filgrastim;   Drug: Antithymocyte globulin;   Drug: Cyclosporine;   Drug: Mycophenolate mofetil;   Drug: rituximab
    Sponsors:   Stanford University;   Stanford University
    Recruiting - verified January 2012
  • Bortezomib (Velcade) Plus Rituximab-HyperCVAD in Patients With Mantle Cell Lymphoma

    Conditions:   Mantle Cell Lymphoma;   Lymphoma
    Interventions:   Drug: Bortezomib;   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Methotrexate;   Drug: Cytarabine;   Drug: Doxorubicin
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Millennium Pharmaceuticals, Inc.
    Recruiting - verified May 2012
  • ALL Adult Consortium Trial: Adult ALL Trial

    Condition:   Acute Lymphoblastic Leukemia
    Interventions:   Drug: Doxorubicin;   Drug: Cytarabine;   Drug: Methotrexate;   Drug: Vincristine;   Drug: Cyclophosphamide;   Drug: Methylprednisone;   Drug: Hydrocortisone Sodium Succinate;   Drug: Dexamethasone;   Drug: 6-MP;   Drug: PEG-Asparaginase;   Drug: Imatinib;   Drug: Etoposide;   Procedure: Radiation Therapy;   Drug: E. coli Asparaginase
    Sponsors:   Dana-Farber Cancer Institute;   Dana-Farber Cancer Institute;   Massachusetts General Hospital;   Children's Hospital Boston
    Recruiting - verified August 2011
  • Fludarabine-Based Conditioning for Allogeneic Marrow Transplantation in Aplastic Anemia

    Condition:   Aplastic Anemia
    Interventions:   Drug: Antithymocyte Globulin;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Radiation: Total Body Irradiation (TBI);   Procedure: Bone Marrow Transplant
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   National Heart, Lung, and Blood Institute (NHLBI);   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • SCT for Dyskeratosis Congenita or SAA

    Conditions:   Dyskeratosis Congenita;   Aplastic Anemia
    Interventions:   Drug: Campath 1H;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Procedure: Total Body Irradiation;   Procedure: Stem Cell Transplantation;   Drug: ATG
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant, Mycophenolate Mofetil, and Cyclosporine in Treating Patients With Fanconi Anemia

    Conditions:   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Childhood Acute Myeloid Leukemia in Remission;   Childhood Myelodysplastic Syndromes;   de Novo Myelodysplastic Syndromes;   Fanconi Anemia;   Previously Treated Myelodysplastic Syndromes
    Interventions:   Drug: fludarabine phosphate;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Procedure: allogeneic bone marrow transplantation;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Other: immunologic technique;   Other: laboratory biomarker analysis;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Vaccine Therapy With or Without Cyclophosphamide in Treating Patients With Recurrent or Refractory Multiple Myeloma

    Condition:   Multiple Myeloma and Plasma Cell Neoplasm
    Interventions:   Biological: MV-NIS;   Drug: cyclophosphamide;   Other: I-123 prior MV-NIS;   Other: I-123 post MV-NIS;   Drug: Liothyronine
    Sponsors:   Mayo Clinic;   Mayo Clinic;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Genes in Predicting Outcome of Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab and Combination Chemotherapy

    Condition:   Lymphoma
    Interventions:   Drug: Rituximab;   Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Prednisone;   Drug: Vincristine;   Genetic: RNA-based gene array studies;   Genetic: Real time PCR gene expression studies;   Genetic: Tissue-array immunohistochemical studies;   Genetic: Immunoglobulin G Fc receptor genotypes determination
    Sponsors:   University of Miami Sylvester Comprehensive Cancer Center;   University of Miami Sylvester Comprehensive Cancer Center
    Recruiting - verified March 2012
  • Hematopoietic Stem Cell Therapy for Patients With Refractory Myasthenia Gravis

    Condition:   Myasthenia Gravis
    Intervention:   Biological: Hematopoietic Stem Cell Transplantation
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma

    Conditions:   Leukemia;   Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: nelarabine;   Drug: pegaspargase;   Drug: prednisone;   Drug: thioguanine;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma or Supratentorial Primitive Neuroectodermal Tumor

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: filgrastim;   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: isotretinoin;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified May 2012
  • Hyper-CVAD Plus Dasatinib in Philadelphia/BCR-ABL Positive ALL

    Conditions:   Acute Lymphoblastic Leukemia;   Leukemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Vincristine;   Drug: Doxorubicin;   Drug: Dexamethasone;   Drug: Dasatinib;   Drug: Methotrexate;   Drug: Ara-C
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Bristol-Myers Squibb
    Recruiting - verified November 2011
  • Low-Dose or High-Dose Vincristine and Combination Chemotherapy in Treating Young Patients With Relapsed B-Cell Acute Lymphoblastic Leukemia

    Condition:   Leukemia
    Interventions:   Biological: filgrastim;   Drug: asparaginase;   Drug: cyclophosphamide;   Drug: cytarabine;   Drug: dexamethasone;   Drug: doxorubicin hydrochloride;   Drug: etoposide phosphate;   Drug: leucovorin calcium;   Drug: mercaptopurine;   Drug: methotrexate;   Drug: pegaspargase;   Drug: prednisone;   Drug: therapeutic hydrocortisone;   Drug: vincristine sulfate;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified February 2012
  • Combination Chemotherapy With or Without Radiation Therapy in Treating Young Patients With Newly Diagnosed Stage III or Stage IV Wilms Tumor

    Conditions:   Kidney Cancer;   Metastatic Cancer
    Interventions:   Biological: dactinomycin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate;   Procedure: therapeutic conventional surgery;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed By Donor Bone Marrow Transplant, Cyclophosphamide, Mycophenolate Mofetil, and Tacrolimus in Treating Patients With Immunodeficiency or Noncancerous Inherited Disorders

    Condition:   Nonneoplastic Condition
    Interventions:   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: tacrolimus;   Procedure: allogeneic bone marrow transplantation;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Other: laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Cancer Institute (NCI);   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • TBI Dose De-escalation for Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: anti-thymocyte globulin (ATG);   Procedure: Total Body Irradiation;   Procedure: Bone Marrow Transplantation;   Drug: Mycophenolate Mofetil;   Drug: Methylprednisolone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Chemotherapy With Low-Dose Radiation for Pediatric Hodgkin Lymphoma

    Condition:   Hodgkin's Lymphoma
    Interventions:   Drug: Adriamycin, Vinblastine, Vincristine, Bleomycin, Etoposide, Nitrogen Mustard (Cyclophosphamide), Prednisone;   Procedure: Radiotherapy;   Drug: Etoposide, Nitrogen Mustard (Cyclophosphamide) , Vincristine, Vinblastine, Adriamycin, Bleomycin, Prednisone
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified June 2011
  • Autologous Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Lymphoma

    Condition:   Lymphoma
    Interventions:   Drug: carmustine;   Drug: cyclophosphamide;   Drug: etoposide;   Procedure: peripheral blood stem cell transplantation;   Radiation: radiation therapy;   Biological: G-CSF
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

    Conditions:   Accelerated Phase Chronic Myelogenous Leukemia;   Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome;   Adult Acute Lymphoblastic Leukemia in Remission;   Adult Acute Myeloid Leukemia in Remission;   Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities;   Adult Acute Myeloid Leukemia With Del(5q);   Adult Acute Myeloid Leukemia With Inv(16)(p13;q22);   Adult Acute Myeloid Leukemia With t(15;17)(q22;q12);   Adult Acute Myeloid Leukemia With t(16;16)(p13;q22);   Adult Acute Myeloid Leukemia With t(8;21)(q22;q22);   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Burkitt Lymphoma;   Childhood Acute Lymphoblastic Leukemia in Remission;   Childhood Acute Myeloid Leukemia in Remission;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Myelodysplastic Syndromes;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Chronic Phase Chronic Myelogenous Leukemia;   Contiguous Stage II Adult Burkitt Lymphoma;   Contiguous Stage II Adult Diffuse Large Cell Lymphoma;   Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Contiguous Stage II Adult Lymphoblastic Lymphoma;   Contiguous Stage II Grade 3 Follicular Lymphoma;   Contiguous Stage II Mantle Cell Lymphoma;   de Novo Myelodysplastic Syndromes;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Noncontiguous Stage II Adult Burkitt Lymphoma;   Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma;   Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma;   Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma;   Noncontiguous Stage II Adult Lymphoblastic Lymphoma;   Noncontiguous Stage II Grade 3 Follicular Lymphoma;   Noncontiguous Stage II Mantle Cell Lymphoma;   Previously Treated Myelodysplastic Syndromes;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Anemia;   Refractory Anemia With Excess Blasts;   Refractory Anemia With Excess Blasts in Transformation;   Refractory Chronic Lymphocytic Leukemia;   Refractory Multiple Myeloma;   Secondary Acute Myeloid Leukemia;   Secondary Myelodysplastic Syndromes;   Splenic Marginal Zone Lymphoma;   Stage I Adult Burkitt Lymphoma;   Stage I Adult Diffuse Large Cell Lymphoma;   Stage I Adult Diffuse Mixed Cell Lymphoma;   Stage I Adult Immunoblastic Large Cell Lymphoma;   Stage I Adult Lymphoblastic Lymphoma;   Stage I Childhood Lymphoblastic Lymphoma;   Stage I Grade 3 Follicular Lymphoma;   Stage I Mantle Cell Lymphoma;   Stage II Childhood Lymphoblastic Lymphoma;   Stage III Adult Burkitt Lymphoma;   Stage III Adult Diffuse Large Cell Lymphoma;   Stage III Adult Diffuse Mixed Cell Lymphoma;   Stage III Adult Immunoblastic Large Cell Lymphoma;   Stage III Adult Lymphoblastic Lymphoma;   Stage III Childhood Lymphoblastic Lymphoma;   Stage III Grade 3 Follicular Lymphoma;   Stage III Mantle Cell Lymphoma;   Stage IV Adult Burkitt Lymphoma;   Stage IV Adult Diffuse Large Cell Lymphoma;   Stage IV Adult Diffuse Mixed Cell Lymphoma;   Stage IV Adult Immunoblastic Large Cell Lymphoma;   Stage IV Adult Lymphoblastic Lymphoma;   Stage IV Childhood Lymphoblastic Lymphoma;   Stage IV Grade 3 Follicular Lymphoma;   Stage IV Mantle Cell Lymphoma
    Interventions:   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: cyclosporine;   Drug: mycophenolate mofetil;   Other: ex-vivo umbilical cord blood expansion;   Procedure: double-unit umbilical cord blood transplantation;   Procedure: biopsy;   Other: immunologic technique;   Other: diagnostic laboratory biomarker analysis
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center;   National Heart, Lung, and Blood Institute (NHLBI)
    Recruiting - verified January 2012
  • Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: carboplatin;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: leucovorin calcium;   Drug: methotrexate;   Drug: thiotepa;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Oncology Group;   National Cancer Institute (NCI)
    Recruiting - verified August 2011
  • Fludarabine-based Conditioning for Severe Aplastic Anemia

    Condition:   Anemia, Aplastic
    Interventions:   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide;   Drug: Cyclophosphamide
    Sponsors:   National Heart, Lung, and Blood Institute (NHLBI);   National Heart, Lung, and Blood Institute (NHLBI);   Blood and Marrow Transplant Clinical Trials Network;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation in Treating Patients Who Are Undergoing an Umbilical Cord Blood Transplant for Hematologic Cancer

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Chronic Myelogenous Leukemia;   Myelofibrosis;   MDS;   Refractory Anemia;   Chronic Lymphocytic Leukemia;   Prolymphocytic Leukemia;   Multiple Myeloma;   Non-Hodgkin's Lymphoma;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed By an Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer

    Conditions:   Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: umbilical cord blood transplantation;   Radiation: total-body irradiation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified December 2011
  • Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy

    Conditions:   Kidney Cancer;   Leukemia;   Lymphoma;   Multiple Myeloma and Plasma Cell Neoplasm;   Myelodysplastic Syndromes
    Interventions:   Biological: anti-thymocyte globulin;   Drug: cyclophosphamide;   Drug: cyclosporine;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Procedure: stem cell transplantation;   Radiation: total-body irradiation;   Drug: methylprednisolone;   Drug: allopurinol;   Drug: filgrastim
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization

    Condition:   Melanoma
    Interventions:   Biological: Dendritic Cell Immunization;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Biological: T Cells;   Biological: Interleukin-2
    Sponsors:   M.D. Anderson Cancer Center;   M.D. Anderson Cancer Center;   Chiron Corporation
    Recruiting - verified March 2012
  • Hematopoietic Stem Cell Support in Patients With Refractory Sarcoidosis

    Condition:   Sarcoidosis
    Intervention:   Biological: Hematopoietic stem cell transplantation
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • Cyclophosphamide and rATG/Rituximab in Patients With Systemic Lupus Erythematosus

    Condition:   Systemic Lupus Erythematosus
    Intervention:   Biological: Hematopoietic stem cell transplantation
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • Stem Cell Transplantation in Idiopathic Inflammatory Myopathy Diseases

    Condition:   MYOPATHY
    Intervention:   Biological: hematopoietic stem cell transplantation
    Sponsors:   Northwestern University;   Richard Burt, MD
    Recruiting - verified April 2012
  • Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

    Condition:   Fanconi Anemia
    Interventions:   Biological: anti-thymocyte globulin;   Biological: filgrastim;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: methylprednisolone;   Biological: Hematopoietic stem cell transplantation
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • A Study to Lower the Occurrences and Severity of Graft-versus-host Disease

    Condition:   Graft vs Host Disease
    Interventions:   Drug: Ara-C;   Drug: Cyclophosphamide;   Drug: MESNA;   Drug: Campath-1H;   Procedure: Total Body Irradiation;   Procedure: Stem cell infusion
    Sponsors:   Baylor College of Medicine;   Baylor College of Medicine;   Texas Children's Hospital;   The Methodist Hospital System
    Recruiting - verified April 2012
  • Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

    Condition:   Breast Cancer
    Interventions:   Drug: Taxotere;   Drug: Adriamycin/Cytoxan;   Drug: docetaxol;   Drug: doxorubicin
    Sponsors:   Baylor Breast Care Center;   Baylor Breast Care Center;   Baylor College of Medicine
    Recruiting - verified November 2011
  • Autologous Transplant for Multiple Myeloma

    Condition:   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide + Mesna;   Drug: Melphalan;   Biological: Granulocyte-colony stimulating factor;   Drug: Dexamethasone
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Stem Cell Transplant for Hemoglobinopathy

    Conditions:   Sickle Cell Disease;   Thalassemia;   Severe Congenital Neutropenia;   Diamond-Blackfan Anemia;   Shwachman-Diamond Syndrome
    Interventions:   Drug: Busulfan, Fludarabine, ATG, TLI;   Drug: Busulfan, Cyclophosphamide, ATG, GCSF;   Drug: Campath, Fludarabine, Cyclophosphamide;   Radiation: Total Body Irradiation;   Procedure: Stem cell infusion
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota;   National Marrow Donor Program
    Recruiting - verified April 2012
  • Stem Cell Transplantation for Hematological Malignancies

    Conditions:   Leukemia, Lymphocytic, Acute;   AML;   MDS
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Busulfan, Cyclophosphamide, Melphalan, G-CSF, ATG
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • Stem Cell Transplant for Hematological Malignancy

    Conditions:   Leukemia, Myeloid, Chronic;   AML;   Leukemia, Lymphocytic, Acute;   MDS;   Leukemia, Lymphocytic, Chronic;   JMML;   Hodgkin's Disease;   Non-hodgkin's Lymphoma;   Multiple Myeloma
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Cyclophosphamide;   Radiation: Total Body Irradiation;   Drug: Busulfan
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified March 2012
  • Post Transplant Donor Lymphocyte Infusion

    Conditions:   Leukemia, Myeloid, Chronic;   Lymphomas;   Multiple Myeloma;   Myelodysplastic Syndrome;   Leukemia, Lymphocytic, Acute;   Leukemia, Lymphocytic, Chronic;   AML
    Interventions:   Procedure: Donor Lymphocyte Infusion;   Drug: Induction Chemotherapy + DLI
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified January 2012
  • T-Cell Depletion and Stem Cell Transplant for Immune Deficiencies and Histiocytic Disorders

    Conditions:   Hemophagocytic Lymphohistiocytosis;   X-Linked Lymphoproliferative Disorders;   Chediak-Higashi Syndrome;   Griscelli Syndrome;   Immunologic Diseases;   Langerhans-Cell Histiocytosis;   Hematologic Diseases
    Interventions:   Procedure: Stem Cell Transplant;   Drug: Myeloablative conditioning regimen
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified April 2012
  • Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia

    Conditions:   Acute Lymphoblastic Leukemia;   Lymphoma, Lymphoblastic
    Interventions:   Drug: Etoposide, cytarabine, vincristine, dexamethasone;   Drug: methotrexate, teniposide, PEG-asparaginase;   Drug: mitoxantrone, cyclophosphamide, mercaptopurine, vinblastine;   Drug: L-asparaginase, erwinia asparaginase;   Procedure: chemotherapy, intrathecal chemotherapy, steroid therapy;   Procedure: Hematopoietic Stem Cell Transplant;   Procedure: Natural Killer (NK) Cell Transplant
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified March 2012
  • Stem Cell Transplant for Juvenile Myelomonocytic Leukemia (JMML)

    Condition:   Juvenile Myelomonocytic Leukemia
    Intervention:   Procedure: Stem Cell Transplant
    Sponsors:   Masonic Cancer Center, University of Minnesota;   Masonic Cancer Center, University of Minnesota
    Recruiting - verified November 2011
  • HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

    Conditions:   Acute Myeloid Leukemia;   Acute Lymphocytic Leukemia;   Myelodysplasia;   Chronic Myeloid Leukemia;   Histiocytosis
    Interventions:   Drug: Chemotherapy and antibodies;   Device: Miltenyi Biotec CliniMACS;   Procedure: Allogeneic stem cell transplantation
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified December 2011
  • Doxorubicin, Cyclophosphamide, and/or Paclitaxel in Treating Women With Nonmetastatic Breast Cancer

    Condition:   Breast Cancer
    Interventions:   Drug: AC regimen;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
    Sponsors:   National Cancer Institute (NCI);   Duke Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified April 2008
  • Umbilical Cord Blood for Stem Cell Transplantation in Treating Young Patients With Malignant or Nonmalignant Diseases

    Conditions:   Childhood Langerhans Cell Histiocytosis;   Fanconi Anemia;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Neuroblastoma;   Sarcoma;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: cyclophosphamide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: methylprednisolone;   Radiation: radiation therapy
    Sponsors:   National Cancer Institute (NCI);   Milton S. Hershey Medical Center
    Recruiting - verified October 2008
  • Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Biological: filgrastim;   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: vincristine sulfate;   Procedure: autologous hematopoietic stem cell transplantation;   Radiation: radiation therapy
    Sponsors:   St. Jude Children's Research Hospital;   St. Jude Children's Research Hospital
    Recruiting - verified January 2012
  • Treating Patients With High-Grade Glioma With IA Carboplatin-based Chemotherapy, With or Without Sodium Thiosulfate

    Conditions:   Brain and Central Nervous System Tumors;   Thrombocytopenia
    Interventions:   Drug: Carboplatin;   Drug: Cyclophosphamide;   Drug: Etoposide phosphate;   Drug: Etoposide;   Drug: Sodium thiosulfate
    Sponsors:   OHSU Knight Cancer Institute;   OHSU Knight Cancer Institute;   National Cancer Institute (NCI)
    Recruiting - verified January 2012
  • Low-Dose Radiation Therapy and Combination Chemotherapy Following Surgery in Treating Children With Newly Diagnosed Primitive Neuroectodermal Tumor or Medulloblastoma

    Condition:   Brain and Central Nervous System Tumors
    Interventions:   Drug: cisplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: lomustine;   Drug: vincristine sulfate
    Sponsors:   National Cancer Institute (NCI);   Children's Hospital of Philadelphia
    Recruiting - verified June 2009
  • Permeability Factor in Focal Segmental Glomerulosclerosis

    Condition:   Focal Glomerulosclerosis
    Interventions:   Procedure: Plasma exchange;   Drug: Cyclophosphamide
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
    Recruiting - verified January 2012
  • EPOCH and Rituximab to Treat Non-Hodgkin's Lymphoma in Patients With HIV Infection

    Conditions:   AIDS Related Lymphoma;   HIV Infection
    Interventions:   Biological: Rituximab;   Biological: filgrastim;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: etoposide;   Drug: vincristine sulfate
    Sponsors:   National Institutes of Health Clinical Center (CC);   National Cancer Institute (NCI)
    Recruiting - verified December 2011
  • Autologous Stem Cell Transplant Followed By Donor Stem Cell Transplant In Treating Patients With Relapsed or Refractory Lymphoma

    Conditions:   Adult Nasal Type Extranodal NK/T-cell Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Burkitt Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Prolymphocytic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Hodgkin Lymphoma;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Adult T-cell Leukemia/Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Splenic Marginal Zone Lymphoma;   Waldenstrom Macroglobulinemia
    Interventions:   Procedure: peripheral blood stem cell transplantation;   Drug: cyclophosphamide;   Radiation: total-body irradiation;   Drug: carmustine;   Drug: etoposide;   Drug: cytarabine;   Drug: melphalan;   Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation;   Drug: fludarabine phosphate;   Drug: mycophenolate mofetil;   Drug: cyclosporine;   Procedure: autologous hematopoietic stem cell transplantation;   Biological: therapeutic autologous lymphocytes
    Sponsors:   Fred Hutchinson Cancer Research Center;   Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium;   National Cancer Institute (NCI)
    Recruiting - verified April 2012
  • Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer

    Conditions:   Chronic Myeloproliferative Disorders;   Leukemia;   Lymphoma;   Myelodysplastic Syndromes;   Myelodysplastic/Myeloproliferative Diseases;   Nonmalignant Neoplasm;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
    Interventions:   Biological: anti-thymocyte globulin;   Drug: busulfan;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: etoposide;   Drug: fludarabine phosphate;   Drug: melphalan;   Drug: thiotepa;   Radiation: total-body irradiation
    Sponsors:   Roswell Park Cancer Institute;   Roswell Park Cancer Institute
    Recruiting - verified December 2011

Main Menu
Clinical Trial Categories
Clinical Trial Locations